Literature DB >> 28091410

Molecular Mechanisms of Increased Heart Rate in Shenxianshengmai-treated Bradycardia Rabbits.

Zhou-Ying Liu1, Jian Huang2, Na-Na Liu2, Min Zheng2, Tao Zhao3, Bu-Chang Zhao3, Yi-Min Wang3, Jie-Lin Pu2.   

Abstract

BACKGROUND: The molecular mechanisms of Shenxianshengmai (SXSM), a traditional Chinese medicine, on bradycardia have been incompletely understood. The study tried to investigate the gene expression profile and proteomics of bradycardia rabbits' hearts after SXSM treatment.
METHODS: Twenty-four adult rabbits were randomly assigned in four groups: sham, model, model plus SXSM treatment, and sham plus SXSM treatment groups. Heart rate was recorded in all rabbits. Then, total RNA of atria and proteins of ventricle were isolated and quantified, respectively. Gene expression profiling was conducted by gene expression chip, and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed to confirm the results of gene expression chip. We used isobaric tags for elative and absolute quantitation and Western blotting to identify altered proteins after SXSM treatment.
RESULTS: There was a constant decrease in the mean heart rate (32%, from 238 ± 6 beats/min to 149 ± 12 beats/min) after six weeks in model compared with that in sham group. This effect was partially reversed by 4-week SXSM treatment. Complementary DNA microarray demonstrated that the increased acetylcholinesterase and reduced nicotinic receptor were take responsibility for the increased heart rate. In addition, proteins involved in calcium handling and signaling were affected by SXSM treatment. Real-time RT-PCR verified the results from gene chip. Results from proteomics demonstrated that SXSM enhanced oxidative phosphorylation and tricarboxylic acid (TCA) cycle in ventricular myocardium to improve ATP generation.
CONCLUSIONS: Long-term SXSM stimulates sympathetic transmission by increasing the expression of acetylcholinesterase and reduces the expression of nicotinic receptor to increase heart rate. SXSM also restored the calcium handling genes and altered genes involved in signaling. In addition, SXSM improves the ATP supply of ventricular myocardium by increasing proteins involved in TCA cycle and oxidation-respiratory chain.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28091410      PMCID: PMC5282675          DOI: 10.4103/0366-6999.197999

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


Introduction

Bradycardia is a condition in which pulse rate is below 60 beats/min. Coronary artery disease patients and elderly people are at a great risk of developing the abnormally slow heart rate.[1] Currently available drugs (e.g., atropine, dopamine, isoproterenol, and epinephrine) treating bradycardia are temporizing measures only in emergency settings. If the patient does not respond to drugs, temporary or permanent cardiac pacemaker is probably indicated.[2] However, the cost of pacing put a huge financial burden on the family. Consequently, an effective drug aiming at increasing heart rate for a long-term is in urgent demand. The Traditional Chinese Medicines have been used to treat arrhythmia for hundreds of years and Shenxianshengmai (SXSM) is one of such medicines. It is a product consisting of eight ingredients including Radix Ginseng Rubra, Herba Epimedii Brevicornus, Fructus Psoraleae, Fructus Lycii, Herba Ephedrae Sinicae, Asarum Heterotropoides, Radix Salviae Miltiorrhizae, and Hirudo. Clinical researches demonstrated that SXSM is effective in treating bradycardia.[34567] However, it has been a mystery how SXSM plays the positive role in treatment. Therefore, we use a bradycardiac animal model to explore the molecular mechanisms of SXSM treatment. Our work will provide new insights into the mechanisms of SXSM.

Methods

Bradycardia model

Twenty-four adult rabbits (Oryctolagus cuniculus) with mean body weight of 2.5 ± 0.5 kg were used for the study. The experimental protocol was performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1985) and the ARRIVE.[8] The Care of Experimental Animals Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College approved the procedures for the care and treatment of animals. The animals were randomly divided into four groups (n = 6 in each group): sham, model, sham plus SXSM (S+SXSM), and model plus SXSM (M+SXSM) groups. Sterilized cotton bud with formaldehyde (37%, SCRC, China) was fixed on the wall of the right atrium, near the entrance of the superior vena cava until heart beat decreased 25–35%.[9] The procedures were the same as the previous study.[10] Then, purified water was administered orally to model group while SXSM (275 mg·kg−1·d−1) was administered to blank plus SXSM and M+SXSM groups. Lead II was used to monitor the electrocardiogram, once every week for 4 weeks. At last, animals were sacrificed 6 weeks later. The procedures in sham and S+SXSM groups were similar to model and M+SXSM groups except that formaldehyde was replaced by purified water. RR, P, PR, QRS, QT, and QTc were calculated before operation (baseline) and 6 weeks’ later, respectively.

RNA and protein preparation

Hearts of the animals were isolated and perfused with purified water. Atria and ventricle of the heart were immediately frozen in liquid nitrogen and then stored at −80°C until use for RNA extraction. MirVana™ mRNA isolation kit (Ambion-1561, USA) was used in accordance with the manufacturer's instructions to isolate total RNA. Then, NanoDrop ND-2000 (Thermo Scientific, USA) and Agilent Bioanalyzer 2100 (Agilent Technologies, USA) were used to quantify RNA and assess the RNA integrity, respectively. To minimize variations attributable to individual rabbit and maximize differences attributable to their genotype, each experiment was performed with RNA pooled from 3 atria. Ventricular tissues were homogenized in 5 volumes (v/w) of isolation buffer (300 mmol/L sucrose, 10 mmol/L Hepes/Na, 500 μmol/L ethylenediaminetetraacetic acid (EDTA)•2Na, pH 7.4, 2 mmol/L phenylmethyl sulfonyl fluoride (PMSF) and 1:1000 diluted Protease Inhibitor Cocktail (Sigma P8340, USA) using a Dounce Glass/Teflon Homogenizer according to the method of Frezza et al.[11] Centrifugation was carried out twice, 800 ×g, 4°C for 10 min.

Gene expression profiling

Total RNA was transcribed to double-strand complementary DNA (cDNA), then synthesized into cRNAs and labeled with Cy3. Labeled cRNAs were hybridized onto Agilent Rabbit Gene Expression Chip (4*4K, Design ID: 020908, containing 43,803 probes) according to manufacturer's instructions and scanned by Agilent Scanner G2505C (Agilent Technologies). Feature Extraction software (version 10.7.1.1, Agilent Technologies) was used to analyze array images to get raw data. Data normalization was performed using GeneSpring. Differentially expressed genes were selected based on fold-change >2.0 and P < 0.05 according to two-way analysis of variance (ANOVA). Gene ontology (GO) database and KEGG were applied to determine functions of these differentially expressed messenger RNAs (mRNAs).[12] Then, differentially expressed genes were researched by Funnet and Uniprot database (http://www.uniprot.org).

Quantitative polymerase chain reaction

SYBR Green quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed on the genes ATP2A1, ERP27, FKBP1B, MBIP, and 18S rRNA (as an internal control) to confirm the results of gene expression chip. Genes were selected from interesting functional groups revealed by GO analysis [Table 1].[1314151617181920212223242526272829303132] Primers were designed with LightCycler Probe Design software 2.0 (Roche Applied Bioscience, Swiss). The cDNA was synthesized at 37°C for 15 min in a 10 μl reaction containing 0.5 μg total RNA, 2 μl PrimerScript Buffer, 0.5 μl oligo dT, 0.5 μl random 6mers and 0.5 μl PrimerScript RT Enzyme Mix I (TaKaRa, Japan). Real-time RT-PCR reactions included 1 μl of cDNA, 5 μl 2 × LightCycler® 480 SYBR Green I master mix (Roche), 0.2 μl forward primer, 0.2 μl reverse primer, and 3.6 μl water of nuclease-free. All PCR reactions were carried out in triplicate with the following conditions: 95°C for 10 min, followed by 40 cycles of 10 s at 95°C, 30 s at 60°C in the LightCycler® 480 II Real-time PCR Instrument (Roche). For each selected gene, melting curve analysis was performed to validate the specific generation of the expected PCR product. The expression of each gene was normalized as ΔCt (Ct of target gene – Ct of internal control gene) using 18S rRNA as the control. Relative quantification using the ΔΔCt method was applied to compare the amounts of mRNA in sham versus model groups and model versus SXSM groups.[33]
Table 1

Candidate genes associated with increased heart rate

FunctionGene symbolProtein nameAverage Log2FC (model)P (model)Average Log2FC (drug)P (drug)
Increase heart rate[1314151617]ACE-1Acetylcholinesterase1.210.026
N-receptor[18]CHRNA2Cholinergic receptor, nicotinic, alpha 2−1.050.0001
Re-uptake Ca2+ to ER[1920]ATP2A1ATPase, Ca2+ transporting, cardiac muscle−1.550.00271.310.003
Protein disulfide isomerase (ER)[21]ERP27Endoplasmic reticulum resident protein 27−2.070.0372.630.005
Calcium homeostasis[222324]FKBP1BFK506-binding protein, 12,600−1.190.0241.130.043
Inhibit MAP3K12, inhibit JNK/SAPK pathway[25]MBIPMAP3K12 binding inhibitory protein 11.110.009−1.110.008
Isomerase, participate in ER redox homeostasis[2627]PPICPeptidylprolyl isomerase C (cyclophilin C)−1.060.0151.260.004
Intracellular signaling pathways[28]PRKCZProtein kinase C, zeta1.710.022−1.750.019
Activate AC[29]VIPR1Vasoactive intestinal polypeptide receptor 12.750.027−2.960.016
Signaling[30]PRLRProlactin receptor−1.570.0041.230.023
Protein phosphorylation[31]NIM1KSerine/threonine-protein kinase NIM15.310.030−3.610.001
UndefinedLOC100355813Olfactory receptor GPCRLTM7−1.090.012−1.030.005
Metalloendopeptidase activity[32]MMP1Matrix metallopeptidase 1 (interstitial collagenase)−1.380.015−1.110.003

FC: Fold change; P: P value calculated from two double-factor variance analysis. ER: Endoplasmic reticulum; SXSM: Shenxianshengmai.

Candidate genes associated with increased heart rate FC: Fold change; P: P value calculated from two double-factor variance analysis. ER: Endoplasmic reticulum; SXSM: Shenxianshengmai.

Protein preparation and isobaric tags for elative and absolute quantitation labeling

Protein preparation from rabbits was performed following the published method[34] with some modifications. Briefly, ventricles from three rabbits were pooled and homogenized in 5 volumes (v/w) of isolation buffer (0.3 mol/L sucrose, 10 mmol/L Hepes-Na, pH 7.0, 0.5 mmol/L EDTA, 2 mmol/L PMSF, and 1:1000 diluted Protease Inhibitor Cocktail [Sigma P8340]) using a Dounce Glass/Teflon Homogenizer. Centrifugations were carried out twice to discard nuclear and cell debris, 800 ×g, 4°C for 10 min. The supernatant was then collected and stored at −80°C. To minimize variations attributable to individual rabbit and maximize differences attributable to their genotype, each experiment was performed with RNA pooled from three ventricles. Equal amounts of protein (75 μg) from each pooled sample were digested with trypsin (0.5 μg/μl) at 37°C for 16h and labeled with unique isobaric tags for elative and absolute quantitation (iTRAQ) reagent (114 for model group, 115 for SXSM group). Labeled samples were pooled and dried in a vacuum centrifuge.

Isobaric tags for elative and absolute quantitation proteomic analysis

The labeled dried peptides were dissolved in mobile phases A (2% acetonitrile [ACN], pH 10.0). Then, samples were loaded on the reversed phase column (Agela, 5 μm, 150 Ε, 4.6 mm × 250 mm,) and separated on an L-3000 HPLC system (Rigol, China) at a flow rate of 1 ml/min. Mobile phase A consisted of 2% ACN and mobile phase B consisted of 98% ACN. Both of them were adjusted pH to 10.0 using NH3•H2O. The gradient used was described as following: 5–8% B, 2 min; 8–18% B, 11 min; 18–32% B, 9 min; 32–95% B, 1 min; 95% B, 1 min; 95–5% B, 2 min. The temperature of Column Oven was set as 60°C. Fractions were collected every minute and then dried in a vacuum centrifuge. Forty fractions were collected and desalted. Then, fractions were combined into twelve fractions and vacuum-dried until analyzed by LC/MS/MS. After dissolved in 0.2% fatty acid and 5% methanol, the dried tryptic peptides loaded and trapped on a precolumn (C18, 100 μm × 20 mm, 5 μm particle size), then separated on an analytical column (C18, 75 μm × 150 mm, 3 μm particle size). Peptides were eluted from the C18 analytical column with 40-min gradient at a flow rate of 350 nL/min on Eksigent Ultra HPLC (AB Sciex). The MS conditions for TripleTOF 5600 were set as the followings: the spray voltage was set of 2.5 kv and the temperature of heater was 150°C. The MS scan range was set at 350 to 1250 m/z and the MS/MS scan range was 100–1500 m/z. Data-dependent acquisition was performed and top 50 precursor ions were selected to fragment using collision induced dissociation (CID). The collision-induced dissociation energy was automatically adjusted by the rolling CID function.

Database search and bioinformatics

The resulting MS/MS data were then compared against data in the NCBI database (Rabbit.protein-20150201) using ProteinPilot™ Software Beta (version 4.5, AB, USA). For protein identification and quantification, peptide mass tolerance and fragment tolerance were each set at 0.3 Da. Only one missed tryptic cleavage was allowed. The false positive rates were controlled below 1%. The following criteria were used to select differentially expressed proteins: (1) proteins including at least one unique high-scoring peptide; (2) P < 0.05; and (3) fold-changes needed to be >2 or <0.5. The UniProt knowledge base (Swiss-Prot/TrEMBL, http://www.uniprot.org/) and GO database were applied to further classify these differentially expressed proteins.

Western blotting

Samples were prepared in SDS sample buffer, separated on 10% SDS gel, and transferred to 0.45 μm polyvinylidene fluoride membranes. The membranes were incubated with primary antibodies for ATPB, and NDUFS1, and with AP-conjugated secondary antibodies. Proteins were detected by BCIP/NBT method following the instruction for the Western blot kit.

Statistical analysis

Electrocardiogram data were expressed as mean ± standard error (SE). Two-way ANOVA was used to test difference of basic parameters between groups. Independent sample t-test was used to estimate difference between groups, with P < 0.05 considered statistically significant. Analyses were performed with SPSS 17.0 (SPSS Inc., Chicago, IL, USA) software.

Results

Effect of long-term Shenxianshengmai treatment on slow heart rate

Representative electrocardiography recordings of sham, model, and SXSM-treated rabbits are illustrated and analyzed in Figure 1 and Table 2, respectively. No difference was observed among baselines of all groups (t = 1.459, P > 0.05). As is evident, chemical injury of sinoatrial node decreased the mean heart rate by 32% (RR interval from 253 ± 10 ms in sham group to 406 ± 35 ms in model group, t = 10.296, P < 0.05, n = 6, respectively) after six weeks. This effect was partially reversed by 4-week SXSM treatment (275 mg·kg−1·d−1, RR interval from 406 ± 35 ms in model group to 251 ± 3 ms in M+SXSM group, t = 10.491, P < 0.05). In addition, SXSM also increased heart rate of sham rabbits (RR interval from 406 ± 35 ms in model group to 186 ± 8 ms in S+SXSM group, P < 0.05). Except for RR interval, SXSM had no significant effect on atrial, atrioventricular, and ventricular conduction parameters, since the P, PR, QRS, and QT interval were not modified [Table 2].
Figure 1

SXSM effects on cardiac electrical activity in anesthetized rabbits. Representative ECG recording (Lead II) obtained in one rabbit from sham (top-left), model (top-right), M+SXSM (bottom-left) and S+SXSM group (bottom-right) under baseline conditions (previous to operation) and after 2 weeks and 6 weeks of treatment. SXSM: Shenxianshengmai; S+SXSM: Sham plus SXSM; M+SXSM: Model plus SXSM; ECG: Electrocardiography; bpm: beats/min.

Table 2

ECG parameters in anesthetized rabbit from sham, control and SXSM before and after treatment groups

GroupsRR (ms)P (ms)PR (ms)QRS (ms)QT (ms)QTc (ms)






BaselineWeek 6BaselineWeek 6BaselineWeek 6BaselineWeek 6BaselineWeek 6BaselineWeek 6
Sham246 ± 10253 ± 1040 ± 040 ± 063 ± 363 ± 323 ± 323 ± 3160 ± 4170 ± 4102 ± 3103 ± 2
Model241 ± 10406 ± 35*40 ± 040 ± 062 ± 160 ± 021 ± 125 ± 3163 ± 3185 ± 11105 ± 293 ± 6
M+SXSM226 ± 8251 ± 340 ± 040 ± 060 ± 061 ± 120 ± 221 ± 3153 ± 4160 ± 2101 ± 1101 ± 1
S+SXSM235 ± 3186 ± 8*40 ± 038 ± 260 ± 058 ± 126 ± 420 ± 1156 ± 2140 ± 0103 ± 1103 ± 2

*P<0.01, model/S + SXSM versus sham group; †P<0.01, M+SXSM versus model group. Data expressed as mean ± SE. n = 6 in each group. ECG parameters obtained in anesthetized rabbit from sham, model, M+SXSM and S+SXSM groups before treatment (baseline) and after 6 weeks of treatment. RR: RR interval; P: P wave duration; PQ: PQ interval; QRS: QRS complex duration; QT: QT interval; QTc: Corrected QT interval. QTc=QT/2√(RR/100); SEM: Standard error of mean; ECG: Electrocardiogram; SXSM: Shenxianshengmai; M+SXSM: Model plus Shenxianshengmai; S+SXSM: Sham plus Shenxianshengmai.

SXSM effects on cardiac electrical activity in anesthetized rabbits. Representative ECG recording (Lead II) obtained in one rabbit from sham (top-left), model (top-right), M+SXSM (bottom-left) and S+SXSM group (bottom-right) under baseline conditions (previous to operation) and after 2 weeks and 6 weeks of treatment. SXSM: Shenxianshengmai; S+SXSM: Sham plus SXSM; M+SXSM: Model plus SXSM; ECG: Electrocardiography; bpm: beats/min. ECG parameters in anesthetized rabbit from sham, control and SXSM before and after treatment groups *P<0.01, model/S + SXSM versus sham group; †P<0.01, M+SXSM versus model group. Data expressed as mean ± SE. n = 6 in each group. ECG parameters obtained in anesthetized rabbit from sham, model, M+SXSM and S+SXSM groups before treatment (baseline) and after 6 weeks of treatment. RR: RR interval; P: P wave duration; PQ: PQ interval; QRS: QRS complex duration; QT: QT interval; QTc: Corrected QT interval. QTc=QT/2√(RR/100); SEM: Standard error of mean; ECG: Electrocardiogram; SXSM: Shenxianshengmai; M+SXSM: Model plus Shenxianshengmai; S+SXSM: Sham plus Shenxianshengmai.

Effects of long-term Shenxianshengmai treatment on cardiac transcripts

To explore the gene expression changes induced by chemical lesions of SA node, we compared sham and model group and identified 102 altered genes, among which 72 genes were downregulated and 30 were upregulated [Supplementary Table 1]. To follow the changes induced by SXSM treatment, we compared model and M+SXSM rabbits and found 109 differentially expressed genes [60 downregulated and 49 upregulated, Supplementary Table 2]. Among these altered genes, a total of 11 genes (ATP2A1, ERP27, FKBP1B, MBIP, PPIC, PRKCZ, VIPR1, PRLR, NIM1K, LOC100355813, and MMP1) were appeared in both model and SXSM originated differentially expressed genes [Supplementary Figure 1]. Moreover, the expressions of nine of them (ATP2A1, ERP27, FKBP1B, MBIP, PPIC, PRKCZ, VIPR1, PRLR, and NIM1K) were restored by SXSM in model rabbits [Table 1].
Supplementary Table 1

Altered genes induced by chemical lesions of SA node

Probe nameP (model)FC ([M-C] vs. [N-C])Log FC ([M-C] vs. [N-C])FC (abs) ([M-C] vs. [N-C])Regulation ([M-C] vs. [N-C])Gene symbolDescription
A_04_P0500872.13E-04−5.90264−2.56136045.902604DownCDHR2Cadherin-related family member 2 (source: HGNC symbol; Acc.:18231) (ENSOCUT00000011957)
A_04_P0870070.023285631−3.5565941−1.83049633.5565941DownNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0870100.028032145−3.750003−1.90689183.750003DownNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0870110.03808915−3.5096507−1.81132753.5096507DownNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0799030.028085012−4.738601−2.24446134.738601DownSLCO6A1Solute carrier organic anion transporter family, member 6A1 (source: HGNC symbol; Acc.: 23613) (ENSOCUT00000003395)
A_04_P0166330.003186869−2.1107936−1.07778552.1107936DownPPARAO. cuniculus mRNA for peroxisome proliferator-activated receptor alpha, partial (Y16420)
A_04_P0002520.022043498−2.3649971−1.24183852.3649971DownSLC17A1O. cuniculus solute carrier family 17 (organic anion transporter), member 1 (SLC17A1), mRNA (NM_001082307)
A_04_P0871120.037798274−2.2228696−1.15242342.2228696DownGALNT6GalNAc-T6 (source: HGNC symbol; Acc.: 4128) (ENSOCUT00000016142)
A_04_P0600830.033848617−2.0396495−1.02832132.0396495DownFAM46APredicted: O. cuniculus FAM46A, transcript variant X1, mRNA (XM_002714547)
A_04_P0707420.011976678−2.6385913−1.39976792.6385913DownLEPRE1Leucine proline-enriched proteoglycan (leprecan) 1 (source: HGNC symbol; Acc.: 19316) (ENSOCUT00000005604)
A_04_P0038110.018036077−2.2830641−1.19097142.2830641DownPOMCPredicted: O. cuniculus POMC, mRNA (XM_008254814)
A_04_P1002170.012590322−2.6345034−1.3975312.6345034DownUNC5Cunc-5 homolog C (C. elegans) (source: HGNC symbol; Acc.: 2569) (ENSOCUT00000027103)
A_04_P0349320.03228504−2.4518998−1.29392.4518998DownCYGBCytoglobin (source: HGNC symbol; Acc.: 16505) (ENSOCUT00000007189)
A_04_P0023270.020543803−3.3467507−1.74276113.3467507DownCRPO. cuniculus CRP, pentraxin-related, mRNA (NM_001082265)
A_04_P0896450.041924737−2.2000206−1.1375172.2000206DownPSD3Pleckstrin and Sec7 domain containing 3 (source: HGNC symbol; Acc.: 19093) (ENSOCUT00000025561)
A_04_P0170860.044797514−3.5483832−1.82716183.5483832DownSERPINF1Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 (source: HGNC symbol; Acc.: 8824) (ENSOCUT00000000092)
A_04_P0896430.029146606−2.290933−1.19593522.290933DownPSD3Pleckstrin and Sec7 domain containing 3 (source: HGNC symbol; Acc.: 19093) (ENSOCUT00000025561)
A_04_P0932490.039436527−2.9985077−1.58424472.9985077DownMMP2O. cuniculus MMP2 (gelatinase A, 72 kDa gelatinase, 72 kDa Type IV collagenase) (MMP2), mRNA (NM_001082209)
A_04_P0516820.015472568−6.1579328−2.6224466.1579328DownMFAP5Microfibrillar associated protein 5 (source: HGNC symbol; Acc.: 29673) (ENSOCUT00000002406)
A_04_P0896440.036751527−2.12099−1.08473782.12099DownPSD3Pleckstrin and Sec7 domain containing 3 (source: HGNC symbol; Acc.: 19093) (ENSOCUT00000025561)
A_04_P0896420.030870933−2.178746−1.1234982.178746DownPSD3Pleckstrin and Sec7 domain containing 3 (source: HGNC symbol; Acc.: 19093) (ENSOCUT00000025561)
A_04_P0896460.04265277−2.2121258−1.14543342.2121258DownPSD3Pleckstrin and Sec7 domain containing 3 (source: HGNC symbol; Acc.: 19093) (ENSOCUT00000025561)
A_04_P0724270.028034508−5.3536167−2.42051395.3536167DownERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0932470.041405607−2.8864455−1.5292942.8864455DownMMP2O. cuniculus MMP2 (gelatinase A, 72 kDa gelatinase, 72 kDa Type IV collagenase) (MMP2), mRNA (NM_001082209)
A_04_P0932480.043032378−2.7668319−1.4682352.7668319DownMMP2O. cuniculus MMP2 (gelatinase A, 72 kDa gelatinase, 72 kDa Type IV collagenase) (MMP2), mRNA (NM_001082209)
A_04_P0042910.015457233−2.0878642−1.06202792.0878642DownPPICPeptidylprolyl isomerase C (cyclophilin C) (source: HGNC symbol; Acc.: 9256) (ENSOCUT00000012051)
A_04_P0932510.039674506−2.8214786−1.49645142.8214786DownMMP2O. cuniculus MMP2 (gelatinase A, 72 kDa gelatinase, 72 kDa Type IV collagenase), mRNA (NM_001082209)
A_04_P0015760.00394646−2.9770167−1.57386732.9770167DownPRLRO. cuniculus PRLR, mRNA (NM_001082231)
A_04_P0885970.02296636−3.065462−1.61610463.065462DownTIAM1T-cell lymphoma invasion and metastasis 1 (source: HGNC symbol; Acc.: 11805) (ENSOCUT00000016533)
A_04_P0018810.023102732−2.0472045−1.03365522.0472045DownLPXNO. cuniculus LPXN, mRNA (NM_001082048)
A_04_P0976990.001263165−2.246798−1.16787052.246798DownTHSD7BThrombospondin, Type I, domain containing 7B (source: HGNC symbol; Acc: 29348) (ENSOCUT00000004498)
A_04_P0724280.038376957−3.8443546−1.94274143.8443546DownERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0724310.04013448−3.8216913−1.93421133.8216913DownERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0351320.044130646−2.5600467−1.35617022.5600467DownPLVAPPlasmalemma vesicle associated protein (source: HGNC symbol; Acc.: 13635) (ENSOCUT00000016885)
A_04_P0061310.009948871−4.4479394−2.15313724.4479394DownCOL3A1Collagen, Type III, alpha 1 (source: HGNC symbol; Acc.: 2201) (ENSOCUT00000015004)
A_04_P0459780.031028168−2.5334647−1.34111172.5334647DownLOC100348745Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1TW35) (ENSOCUT00000022052)
A_04_P0724290.039589465−3.929553−1.97436523.929553DownERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0564320.03142421−4.6996303−2.23254734.6996303DownSTAC2SH3 and cysteine rich domain 2 (source: HGNC symbol; Acc.: 23990) (ENSOCUT00000014912)
A_04_P1021480.018136093−2.338483−1.22557312.338483DownLOC100348745Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1TW35) (ENSOCUT00000022052)
A_04_P0823840.047478992−2.9464633−1.55898432.9464633DownLOC100354746L-3-hydroxyproline dehydratase (trans-) (source: HGNC symbol; Acc.: 20488) (ENSOCUT00000013400)
A_04_P0334090.003330424−2.0835822−1.0590662.0835822DownCCNE2Cyclin E2 (source: UniProtKB/TrEMBL; Acc.: A8UKE8) (ENSOCUT00000005398)
A_04_P0384920.010132602−2.2381797−1.16232592.2381797DownDUSP21Dual specificity phosphatase 21 (source: HGNC symbol; Acc.: 20476) (ENSOCUT00000009967)
A_04_P0585920.040390886−2.7010481−1.43351942.7010481DownGPX7O. cuniculus GPX7, mRNA (NM_001256904)
A_04_P0598270.01597391−2.5964324−1.37653062.5964324DownLOC100340044Nephronophthisis 4 (source: HGNC symbol; Acc.: 19104) (ENSOCUT00000002222)
A_04_P0957970.03869427−6.470327−2.69383866.470327DownNDUFAF2NADH dehydrogenase (ubiquinone) complex I, assembly factor 2 (source: HGNC symbol; Acc.: 28086) (ENSOCUT00000004524)
A_04_P0957990.03740461−6.1531677−2.62132936.1531677DownNDUFAF2NADH dehydrogenase (ubiquinone) complex I, assembly factor 2 (source: HGNC symbol; Acc.: 28086) (ENSOCUT00000004524)
A_04_P0996020.015056029−3.599814−1.84792233.599814DownCOL3A1Collagen, Type III, alpha 1 (source: HGNC symbol; Acc.: 2201) (ENSOCUT00000015004)
A_04_P0996030.020265575−3.3484626−1.74349883.3484626DownCOL3A1Collagen, Type III, alpha 1 (source: HGNC symbol; Acc.: 2201) (ENSOCUT00000015004)
A_04_P0925870.036181234−2.9673595−1.56917982.9673595DownANLNPredicted: O. cuniculus anillin, actin binding protein (ANLN), transcript variant X4, mRNA (XM_008261645)
A_04_P0544490.01497467−2.6039603−1.38070752.6039603DownMMP1O. cuniculus MMP1(interstitial collagenase), mRNA (NM_001171139)
A_04_P0839480.03093418−2.1244−1.08705542.1244DownLOC100358172Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1TBJ2) (ENSOCUT00000016394)
A_04_P0996050.019832825−3.3901873−1.76136493.3901873DownCOL3A1Collagen, Type III, alpha 1 (source: HGNC symbol; Acc.: 2201) (ENSOCUT00000015004)
A_04_P0332870.01829139−2.8958638−1.53399372.8958638DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0293020.02377222−3.152118−1.65632153.152118DownCOL3A1Collagen, Type III, alpha 1 (Source: HGNC symbol; Acc.: 2201) (ENSOCUT00000015004)
A_04_P0615120.04516693−2.5043848−1.32445622.5043848DownECM2Extracellular matrix protein 2, female organ and adipocyte specific (source: HGNC symbol; Acc.: 3154) (ENSOCUT00000008293)
A_04_P0037210.021280957−5.6962433−2.51001075.6962433DownCOL1A1nbc40c08.y1 Rabbit trigeminal nerve. Unnormalized (nbc) O. cuniculus cDNA clone nbc40c08 5’, mRNA sequence (EB378353)
A_04_P0135770.042669218−2.1812866−1.12517932.1812866DownSLC4A7O. cuniculus SLC4A7, mRNA (NM_001195836)
A_04_P0532220.001118318−2.0266144−1.01907162.0266144DownLOC100356056Olfactory receptor, family 5, subfamily K, member 3 (source: HGNC symbol; Acc.: 31290) (ENSOCUT00000021390)
A_04_P0044320.019337988−5.1568594−2.36649275.1568594DownGSTM2O. cuniculus glutathione S-transferase mu 2 (muscle) (GSTM2), mRNA (NM_001082252)
A_04_P0996040.03374342−2.9723594−1.57160852.9723594DownCOL3A1Collagen, Type III, alpha 1 (source: HGNC symbol; Acc.: 2201) (ENSOCUT00000015004)
A_4_P0979170.014595655−2.363482−1.24091392.363482DownDNAH11Dynein, axonemal, heavy chain 11 (source: HGNC symbol; Acc.: 2942) (ENSOCUT00000014002)
A_04_P0679880.025094591−2.113492−1.07962862.113492DownPOLQPolymerase (DNA directed), theta (source: HGNC symbol; Acc.: 9186) (ENSOCUT00000008087)
A_04_P0802260.04116367−2.2043643−1.14036272.2043643DownFASO. cuniculus Fas cell surface death receptor (FAS), mRNA (NM_001081995)
A_04_P0051060.029306017−3.483605−1.8005813.483605DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0802230.017979171−2.6730063−1.41846322.6730063DownFASO. cuniculus Fas cell surface death receptor (FAS), mRNA (NM_001081995)
A_04_P0758390.04102744−2.7049184−1.4355852.7049184DownKDELR3KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 (source: HGNC symbol; Acc.:6306) (ENSOCUT00000004978)
A_04_P0802250.047294028−2.5963895−1.37650682.5963895DownFASO. cuniculus Fas cell surface death receptor (FAS), mRNA (NM_001081995)
A_04_P0021130.002724072−2.9282255−1.55002672.9282255DownATP2A1O. cuniculus ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 (ATP2A1), mRNA (NM_001089318)
A_04_P0758380.04812213−2.6296778−1.3948862.6296778DownKDELR3KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 (source: HGNC symbol; Acc.: 6306) (ENSOCUT00000004978)
A_04_P0831550.027226511−3.4746482−1.79686693.4746482DownFGF12Fibroblast growth factor 12 (source: HGNC symbol; Acc.: 3668) (ENSOCUT00000007581)
A_04_P0958020.035368208−2.8162816−1.49379162.8162816DownTP63Tumor protein p63 (source: HGNC symbol; Acc.: 15979) (ENSOCUT00000016469)
A_04_P0299670.027289847−3.2396457−1.69583613.2396457DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0518670.026114652−4.3361998−2.11643124.3361998DownKAZALD1Kazal-type serine peptidase inhibitor domain 1 (source: HGNC symbol; Acc.: 25460) (ENSOCUT00000002973)
A_04_P0050110.027014492−2.4109325−1.26959132.4109325DownSPARCSPARC (source: UniProtKB/Swiss-Prot; Acc.: P36233) (ENSOCUT00000012119)
A_04_P0079760.047936346−2.7027574−1.4344322.7027574DownFBN1Fibrillin 1 (source: HGNC symbol; Acc.: 3603) (ENSOCUT00000033355)
A_04_P0802220.04711833−2.5315278−1.34000832.5315278DownFASO. cuniculus FAS death receptor, mRNA (NM_001081995)
A_04_P0051070.03109285−3.681179−1.8801683.681179DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0921670.02343565−3.664335−1.87355143.664335DownPDLIM3PDZ and LIM domain 3 (source: HGNC symbol; Acc.: 20767) (ENSOCUT00000005808)
A_04_P0163980.024049735−2.2937021−1.19767812.2937021DownFKBP1Bnbc39d02.x1 Rabbit trigeminal nerve. Unnormalized (nbc) O. cuniculus cDNA clone nbc39d02 3’, mRNA sequence (EB378230)
A_04_P0831530.02726263−3.4423661−1.78340053.4423661DownFGF12Fibroblast growth factor 12 (source: HGNC symbol; Acc.: 3668) (ENSOCUT00000007581)
A_04_P0051099 0.0369753−3.5455344−1.82600313.5455344DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0332950.03675723−3.8002567−1.92609693.8002567DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0332960.031819753−3.8275986−1.93643953.8275986DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0336630.002227771−2.3468587−1.2307312.3468587DownLOC100356573PREDICTED: O. cuniculus olfactory receptor 183-like (LOC100356573), mRNA (XM_008267070)
A_04_P0332940.031522974−3.9890788−1.99605563.9890788DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0332930.030434528−3.9730337−1.9902413.9730337DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0831520.026679767−3.68019−1.87978033.68019DownFGF12Fibroblast growth factor 12 (source: HGNC symbol; Acc.:3668) (ENSOCUT00000007581)
A_04_P0345320.011843006−2.131761−1.09204582.131761DownLOC100355813Predicted: O. cuniculus putative olfactory receptor GPCRLTM7 (LOC100355813), mRNA (XM_008269585)
A_04_P0332920.032284934−3.7423513−1.9039453.7423513DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0419220.035629585−2.813322−1.49227482.813322DownBEX4Brain expressed, X-linked 4 (source: HGNC symbol; Acc.: 25475) (ENSOCUT00000000444)
A_04_P0419230.039250128−3.5689461−1.83549813.5689461DownBEX4Brain expressed, X-linked 4 (source: HGNC symbol; Acc.: 25475) (ENSOCUT00000000444)
A_04_P0831540.02627617−3.6316636−1.86063053.6316636DownFGF12Fibroblast growth factor 12 (source: HGNC symbol; Acc.: 3668) (ENSOCUT00000007581)
A_04_P1004670.037227023−2.2789202−1.18835042.2789202DownPPFIA2Predicted: O. cuniculus PTPRF, interacting protein (liprin), PPFIA2, mRNA (XM_008256846)
A_04_P0286510.028550228−2.975188−1.57298092.975188DownCCDC80Coiled-coil domain containing 80 (source: HGNC symbol; Acc.: 30649) (ENSOCUT00000022757)
A_04_P0051080.040823817−3.2330394−1.69289113.2330394DownCOL1A2O. cuniculus COL1A2, mRNA (NM_001195668)
A_04_P0369020.04764918−3.0791728−1.62254293.0791728DownANGPTL4Angiopoietin-like 4 (source: HGNC symbol; Acc.: 16039) (ENSOCUT00000016598)
A_04_P0827320.04945613−2.3887203−1.2562382.3887203DownCBR3Carbonyl reductase 3 (source: HGNC symbol; Acc.: 1549) (ENSOCUT00000016753)
A_04_P0804440.01253518−2.367927−1.24362472.367927DownITIH5Inter-alpha-trypsin inhibitor heavy chain family, member 5 (source: HGNC symbol; Acc.: 21449) (ENSOCUT00000016950)
A_04_P0804430.01416163−2.3782194−1.24988172.3782194DownITIH5Inter-alpha-trypsin inhibitor heavy chain family, member 5 (source: HGNC symbol; Acc.: 21449) (ENSOCUT00000016950)
A_04_P0899370.012976293−5.5949855−2.48413445.5949855DownLOC100346910Cytochrome P450, family 26, subfamily A, polypeptide 1 (source: HGNC symbol; Acc.: 2603) (ENSOCUT00000000178)
A_04_P0004160.027141394−2.9160402−1.54401062.9160402DownSLC5A11O. cuniculus solute carrier family 5 (sodium/inositol cotransporter), member 11 (SLC5A11), mRNA (NM_001082193)
A_04_P0804450.013871072−2.3409014−1.22706412.3409014DownITIH5Inter-alpha-trypsin inhibitor heavy chain family, member 5 (source: HGNC symbol; Acc.: 21449) (ENSOCUT00000016950)
A_04_P0897870.033155497−2.0099761−1.00717832.0099761DownCTTNBP2O. cuniculus CTTNBP2, mRNA (NM_001171037)
A_04_P0698260.00699335−2.9462788−1.55889392.9462788DownC16H1orf100Predicted: O. cuniculus chromosome 16 open reading frame, human C1orf100 (C16H1orf100), mRNA (XM_008268175)
A_04_P0804460.010715441−2.386099−1.25465392.386099DownITIH5Inter-alpha-trypsin inhibitor heavy chain family, member 5 (source: HGNC symbol; Acc.: 21449) (ENSOCUT00000016950)
A_04_P0986520.036045354−2.3227742−1.21584892.3227742DownLOXL2Lysyl oxidase-like 2 (source: HGNC symbol; Acc.: 6666) (ENSOCUT00000014596)
A_04_P0579620.021160344−2.3215833−1.2151092.3215833DownCREB3L1cAMP responsive element binding protein 3-like 1 (source: HGNC symbol; Acc.: 18856) (ENSOCUT00000004418)
A_04_P0354520.028131086−2.155412−1.10796362.155412DownORYCUNV1R1649O. cuniculus vomeronasal 1 receptor oryCunV1R1649 (ORYCUNV1R1649), mRNA (NM_001167331)
A_04_P0690530.031732317−2.417458−1.27349092.417458DownASXL3Additional sex combs like 3 (Drosophila) (source: HGNC symbol; Acc.: 29357) (ENSOCUT00000021269)
A_04_P0897910.028787576−2.3628736−1.24054242.3628736DownCTTNBP2O. cuniculus CTTNBP2, mRNA (NM_001171037)
A_04_P0698220.001974626−2.0158546−1.01139162.0158546DownC16H1orf100Predicted: O. cuniculus chromosome 16 open reading frame, human C1orf100 (C16H1orf100), mRNA (XM_008268175)
A_04_P0821770.026941413−4.7234235−2.23983294.7234235DownCHST9Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 (source: HGNC symbol; Acc.: 19898) (ENSOCUT00000004444)
A_04_P0715280.045763444−4.0166063−2.00597724.0166063DownCXXC4CXXC finger protein 4 (source: HGNC symbol; Acc.:24593) (ENSOCUT00000015532)
A_04_P0142660.009920757−2.1841376−1.12706382.1841376DownTHO. cuniculus tyrosine hydroxylase mRNA, partial cds (AF493546)
A_04_P0510420.0245454482.89766671.53489162.8976667UpTMEM30BPredicted: O. cuniculus TMEM30B, mRNA (XM_002719548)
A_04_P0023010.014152972.1159441.08130152.115944UpBCL2L1O. cuniculus BCL2L1, mRNA (NM_001082135)
A_04_P0273060.0168626899.8469983.2996849.846998UpVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T4R1) (ENSOCUT00000013108)
A_04_P0681840.0208268973.54681421.82652383.5468142UpPCBP3Poly(rC) binding protein 3 (source: HGNC symbol; Acc.: 8651) (ENSOCUT00000002697)
A_04_P0681820.026858252.92116171.54654222.9211617UpPCBP3Poly(rC) binding protein 3 (source: HGNC symbol; Acc.:8651) (ENSOCUT00000002697)
A_04_P0681830.0179933553.2459341.69863373.245934UpPCBP3Poly(rC) binding protein 3 (source: HGNC symbol; Acc.: 8651) (ENSOCUT00000002697)
A_04_P0400430.0115454094.7173172.23796654.717317UpIFIT1BPredicted: O. cuniculus IFIT1B, transcript variant X2, mRNA (XM_008270168)
A_04_P0273090.0161331079.8386053.29845389.838605UpVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T4R1) (ENSOCUT00000013108)
A_04_P0681860.0235521853.9179721.97010713.917972UpPCBP3Poly(rC) binding protein 3 (source: HGNC symbol; Acc.: 8651) (ENSOCUT00000002697)
A_04_P0129770.028763072.65109591.40658882.6510959UpPPP2R2CO. cuniculus protein phosphatase 2, regulatory subunit B, gamma (PPP2R2C), mRNA (NM_001171076)
A_04_P0681850.0294493343.73249861.90014173.7324986UpPCBP3Poly(rC) binding protein 3 (source: HGNC symbol; Acc.: 8651) (ENSOCUT00000002697)
A_04_P0039120.0143549262.91542651.54370692.9154265UpSLC2A3Solute carrier family 2, facilitated glucose transporter member 3 (source: UniProtKB/TrEMBL; Acc.: G1TI27) (ENSOCUT00000024311)
A_04_P0273070.0223135787.32529162.87288627.3252916UpVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T4R1) (ENSOCUT00000013108)
A_04_P0741370.0289307374.797342.26223474.79734UpLOC100345657DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (source: HGNC symbol; Acc.: 25942) (ENSOCUT00000006364)
A_04_P0741380.038782984.21390442.07515764.2139044UpLOC100345657DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (source: HGNC symbol; Acc.: 25942) (ENSOCUT00000006364)
A_04_P0576890.0319227582.00322911.00232742.0032291UpNOSTRINNitric oxide synthase trafficking (source: HGNC symbol; Acc.: 20203) (ENSOCUT00000005730)
A_04_P0400420.0229284044.02358632.0084824.0235863UpIFIT1BPredicted: O. cuniculus IFIT1B, transcript variant X2, mRNA (XM_008270168)
A_04_P0036260.046898842.64116791.4011762.6411679UpPLA2G1BPhospholipase A2, group IB (pancreas) (source: HGNC symbol; Acc.:9030) (ENSOCUT00000001103)
A_04_P0273080.0303656637.03538132.81462867.0353813UpVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.:G1T4R1) (ENSOCUT00000013108)
A_04_P0273100.0250734026.46451662.69254266.4645166UpVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T4R1) (ENSOCUT00000013108)
A_04_P0823580.0119403522.75298711.46099782.7529871UpSTACSH3 and cysteine rich domain (source: HGNC symbol; Acc.: 11353) (ENSOCUT00000014575)
A_04_P0039140.0264115072.30127841.20243552.3012784UpSLC2A3Solute carrier family 2, facilitated glucose transporter member 3 (source: UniProtKB/TrEMBL; Acc.: G1TI27) (ENSOCUT00000024311)
A_04_P0484670.00654353112.8970113.688964812.897011UpFABP2Fatty acid binding protein 2, intestinal (source: HGNC symbol; Acc.: 3556) (ENSOCUT00000003292)
A_04_P0984220.0401979422.0004061.00029282.000406UpEXOC4Exocyst complex component 4 (source: HGNC symbol; Acc.: 30389) (ENSOCUT00000011683)
A_04_P1010470.032082153.6118111.85272243.611811UpSLC1A2Solute carrier family 1 (glial high affinity glutamate transporter), member 2 (source: HGNC symbol; Acc.: 10940) (ENSOCUT00000000717)
A_04_P0039130.0159445352.8136841.49246032.813684UpSLC2A3Solute carrier family 2, facilitated glucose transporter member 3 (source: UniProtKB/TrEMBL; Acc.: G1TI27) (ENSOCUT00000024311)
A_04_P0500540.0103263082.15978261.11088612.1597826UpPPP1R8Protein phosphatase 1, regulatory subunit 8 (source: HGNC symbol; Acc.: 9296) (ENSOCUT00000003550)
A_04_P0500550.0088466622.17339281.11994892.1733928UpPPP1R8Protein phosphatase 1, regulatory subunit 8 (source: HGNC symbol; Acc.: 9296) (ENSOCUT00000003550)
A_04_P0022610.0223262313.27830651.71295073.2783065UpPRKCZO. cuniculus PRKCZ, mRNA (NM_001082758)
A_04_P0500560.0144069042.1204111.08434392.120411UpPPP1R8Protein phosphatase 1, regulatory subunit 8 (Source: HGNC symbol; Acc.:9296) (ENSOCUT00000003550)
A_04_P0774520.0412243162.33386181.22271922.3338618UpSOCS2Predicted: O. cuniculus SOCS2, mRNA (XM_002711201)
A_04_P0774560.0469245462.20670581.14189432.2067058UpSOCS2SOC2 (source: HGNC symbol; Acc.:19382) (ENSOCUT00000010933)
A_04_P0774530.0493249862.249361.16951472.24936UpSOCS2Predicted: O. cuniculus SOCS2, mRNA (XM_002711201)
A_04_P0024380.0206006622.0168591.01211022.016859UpSTK17AO. cuniculus STK17A, mRNA (NM_001082006)
A_04_P0039150.0313438482.15005351.10437252.1500535UpSLC2A3Solute carrier family 2, facilitated glucose transporter member 3 (source: UniProtKB/TrEMBL; Acc.: G1TI27) (ENSOCUT00000024311)
A_04_P0024370.0115383882.01757841.01262472.0175784UpSTK17AO. cuniculus STK17A, mRNA (NM_001082006)
A_04_P0017960.047315383.13536831.64863493.1353683UpCA4O. cuniculus CA4, mRNA (NM_001082372)
A_04_P0003660.043427492.7414141.45492032.741414UpPGRO. cuniculus PGR, mRNA (NM_001082267)
A_04_P0928350.0295300976.57301862.7165566.5730186UpFGF16Fibroblast growth factor 16 (source: HGNC symbol; Acc.: 3672) (ENSOCUT00000007573)
A_04_P0928320.0287045116.44593142.68838886.4459314UpFGF16Fibroblast growth factor 16 (source: HGNC symbol; Acc.: 3672) (ENSOCUT00000007573)
A_04_P0928340.0302335666.4200132.68257626.420013UpFGF16Fibroblast growth factor 16 (source: HGNC symbol; Acc.: 3672) (ENSOCUT00000007573)
A_04_P0848320.0153584492.26156951.17732432.2615695UpMBIPMAP3K12 binding inhibitory protein 1 (source: HGNC symbol; Acc.: 20427) (ENSOCUT00000017089)
A_04_P0928330.026620346.4955812.69945866.495581UpFGF16Fibroblast growth factor 16 (source: HGNC symbol; Acc.: 3672) (ENSOCUT00000007573)
A_04_P0003670.0280901082.27791071.18771122.2779107UpPGRO. cuniculus PGR, mRNA (NM_001082267)
A_04_P0950070.0338628742.74889951.45885422.7488995UpB3GAT2Beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S) (source: HGNC symbol; Acc.: 922) (ENSOCUT00000017143)
A_04_P0590470.0117402382.07312131.05180452.0731213UpCD82CD82 molecule (source: HGNC symbol; Acc.: 6210) (ENSOCUT00000000861)
A_04_P0140400.0236183522.2056751.14122012.205675UpKCNE2O. cuniculus KCNE2, mRNA (NM_001198937)
A_04_P0681970.0193581192.32872461.21954012.3287246UpETV3LETS variant 3-like (source: HGNC symbol; Acc.: 33834) (ENSOCUT00000009586)
A_04_P0848330.0068480392.13740941.09586332.1374094UpMBIPMAP3K12 binding inhibitory protein 1 (Source: HGNC symbol; Acc.: 20427) (ENSOCUT00000017089)
A_04_P0848340.0070912712.0882371.06228542.088237UpMBIPMAP3K12 binding inhibitory protein 1 (source: HGNC symbol; Acc.: 20427) (ENSOCUT00000017089)
A_04_P0140380.0069600962.10082821.07095812.1008282UpKCNE2O. cuniculus KCNE2, mRNA (NM_001198937)
A_04_P0710880.0157790972.05215531.03713992.0521553UpCSF2O. cuniculus CSF 2 (granulocyte-macrophage) mRNA (NM_001171257)
A_04_P0035010.0475696473.2015831.67878533.201583UpS100A8S100 calcium binding protein A8 (source: HGNC symbol; Acc.:10498) (ENSOCUT00000009566)
A_04_P0356960.0240719363.44063831.78267623.4406383UpTUBAL3Tubulin, alpha-like 3 (source: HGNC symbol; Acc.: 23534) (ENSOCUT00000015599)
A_04_P0131300.0460585843.95314071.98299933.9531407UpS100A8S100 calcium binding protein A8 (Source: HGNC symbol; Acc.: 10498) (ENSOCUT00000009566)
A_04_P0131260.046383954.00998742.00359774.0099874UpS100A8O. cuniculus mRNA for MRP-8, partial cds (D17405)
A_04_P0035020.0388705773.50229121.80829913.5022912UpS100A8S100 calcium binding protein A8 (source: HGNC symbol; Acc.: 10498) (ENSOCUT00000009566)
A_04_P0609340.0149024582.024081.01726632.02408UpSLC17A5O. cuniculus SLC17A5, mRNA (NM_001171293)
A_04_P0035030.035595433.65325781.86918353.6532578UpS100A8S100 calcium binding protein A8 (source: HGNC symbol; Acc.: 10498) (ENSOCUT00000009566)
A_04_P0035050.03731693.5386061.82318123.538606UpS100A8S100 calcium binding protein A8 (source: HGNC Symbol; Acc.: 10498) (ENSOCUT00000009566)
A_04_P0035040.03456013.73857071.90248683.7385707UpS100A8S100 calcium binding protein A8 (source: HGNC symbol; Acc.: 10498) (ENSOCUT00000009566)


Probe nameSequence

A_04_P050087AAGTGGATTTCGTCTCTAAGGATGGGACCACATTGCCTTTGCAAAACGTCTTTGAGATCC
A_04_P087007AAGAAAGGGTCCCGTGTCTACAGGGGCATAAGACACACGTCCAAATTTTGTTCAATTTTA
A_04_P087010AAGGGAAAGATGCTCGAAGCTCAATCACAGGGGTCTATAGAATCATTTTACATAGAGTCC
A_04_P087011AGAACACATTCGAAATAATCAAGGGAAAGATGCTCGAAGCTCAATCACAGGGGTCTATAG
A_04_P079903CTGTTGCATTTTATGTATATAAAGGTATTAGAAAGGAAAGCACTGAAAGCTTGCCTATGC
A_04_P016633CAAGAGATCTACAGAGACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTT
A_04_P000252TGGTTTAAAATCTTCCTCCTGATGTCCATCATTAATGTGATAAGCGTGATTTTCTACCTT
A_04_P087112AAGATTTTCTACAGGAGAAATCTACAGGCAGCCAAGATGGCCCAAGAGAAATCCTTTGGG
A_04_P060083AAGACAGACTTTAAATCTTATCACAATGCTGGCTATCCGGGTGCTAGCTGACCAGAACGT
A_04_P070742TCTATTTCACAGAACTGGATGCCAAGACTGTGACGGCAGAGGTACAGCCCCAGTGCGGCA
A_04_P003811CCGCTGGTGACGCTGTTCCGCAACGCCATCGTCAAGAACGCGCACAAGAAGGGCCCGTGA
A_04_P034932TTAAGATCCTCTCTGGGGTCATCCTGGAGGTGATCGCCGAGGAGTTTGCCAACGACTTCC
A_04_P002327GGGGCCAGTTGTGGGGGTCTTAATGCTCTTATTCTATCATGATTCCAGTTTGAGAAAAAA
A_04_P089645TGTGGGAGAAACTCAAGAACGAGAGAGAGTTTTAGTACACTTCTCCAATAGATATTTTTA
A_04_P017086TTGAGAGGAAGCTGCGGATAAAATCCAGCTTCGTGGCACCGCTGGAGAAGGCGTATGGGA
A_04_P089643TTATTGTAATCCAGACACCATTGCTTCACAAGATGGAGTCCATTGCCTTACCTGTGCTAT
A_04_P093249ACTTATTACCTGAAGCTCGAGAACCAAAGTCTGAAGAGCGTGAAGGTTGGAAGCATCAAG
A_04_P051682AGATGATCCCAATCTGGTGAATGAGCCCTCTACAGATGAAACAGTTCTGGCTGATATCGA
A_04_P089644CACTTCTCCAATAGATATTTTTATTGTAATCCAGACACCATTGCTTCACAAGATGGAGTC
A_04_P089642TTGCTTCACAAGATGGAGTCCATTGCCTTACCTGTGCTATGATGCTTCTCAATACGGATC
A_04_P089646TTTTTTAAGGCTTTTTCTCTTGTGGGAGAAACTCAAGAACGAGAGAGAGTTTTAGTACAC
A_04_P072427TTCCTAGAAGGGAAACTGTTGAGAGAAAATCATGAATCAGAAGAAAAGACTCCAAAGGTG
A_04_P093247TTATTACCTGAAGCTCGAGAACCAAAGTCTGAAGAGCGTGAAGGTTGGAAGCATCAAGAC
A_04_P093248CTTATTACCTGAAGCTCGAGAACCAAAGTCTGAAGAGCGTGAAGGTTGGAAGCATCAAGA
A_04_P004291ATATGGATACAAGGGAAGCAGCTTTCATCGGGTCATCAAGGATTTCATGATCCAAGGAGG
A_04_P093251TTCTTCAAGGGCACTTATTACCTGAAGCTCGAGAACCAAAGTCTGAAGAGCGTGAAGGTT
A_04_P001576AACAACATCCTGGTGTTAGTGCAAGATCCAGGAGCTCAAAACGTGGCTTTGTTTGAAGAG
A_04_P088597TTCCAAACAGAAGAAGAAGCTGGTAGGATCTCACAGGCTTTCCATTTATGAGGAGTGGGA
A_04_P001881AAGGACAAGAAGCCATATTGCCGAAAGGATTTCTTAGCCATGTTCTCACCCAAGTGTGGT
A_04_P097699TTTTAAAGGATGGTCTCTTCAGCCACTTGATCCAGATGGCCGAGTAAAAATGTGGGTTTA
A_04_P072428ATTGAGCATGTGCAAAACTTTTATGATGGATTCCTAGAAGGGAAACTGTTGAGAGAAAAT
A_04_P072431TTCAAACTGAAGAAGTCTCAGCTACCAGCTTTGACGATTTATCGAACTCTAGATGATGAG
A_04_P035132ACAAGGAGAAGTTTGAGACGGATGCACAGAGCCTCTGGAGAGACTCCATCATCTCCCGCG
A_04_P006131ACTGCTGGTGAACCTGGAAGAGACGGAAACCCTGGATCAGATGGTCAGCCAGGCAGAGAT
A_04_P045978TTGTTCTTCAAGACTGGTTCTTGCAGGATGCTTCATAAAACTCTGTCCACTTGTGCCTCC
A_04_P072429TGGGATGCACTGCCCATTACAGAAGTTTCAATTGAGCATGTGCAAAACTTTTATGATGGA
A_04_P056432CTGGGAACAAGGAACAGGGTTACATGAGCCTCAAGGAGAACCAGATCTGTGTGGGCGTGG
A_04_P102148TTGTTCTTCAAGACTGGTTCTTGCAGGATGCTTCATAAAACTCTGTCCACTTGTGCCTCC
A_04_P082384GGACTGCAAGCCTTATAATAGAAGAAGATGACCCACTGAGGGATGGCTTTCTTCTCAAGT
A_04_P033409TGCCTTTTGTTAGTGTCATAAAAAGTACGTGTCCAGTGAAGCTGAAGACTTTTAAGAAGA
A_04_P038492CACAGTAAAAATGATCAGCTCGCCAGTGGGTGTGATTCCTGACATCTACCACAAAGAAGT
A_04_P058592ACTTCTACGACTTCAAGGTGGTCAACATCCGGGGCAAGCTGGTGTCGCTGGAGAAGTACC
A_04_P059827ATCTACGTCAACGACCACGAGGACAAGAACGAGGAGGCCTTCTGCGTGAAGGTCACCTAC
A_04_P095797TCAAACTCAAATTAAAGGGCATGCCTCTGCTCCATACTTCGGGAAGCAAGAACCTTCAGT
A_04_P095799GTTCAAACTCAAATTAAAGGGCATGCCTCTGCTCCATACTTCGGGAAGCAAGAACCTTCA
A_04_P099602TATGATATTGGTGGTCCTGATCAAGAATTTGGTGCGGACGTTGGCCCTGTTTGCTTTTTA
A_04_P099603ACGCAAGGCTGTGAGACTACCCATTATAGATATTGCACCCTATGATATTGGTGGTCCTGA
A_04_P092587CTTGTTGATATTCGCCTCTGGCAACCTGATGCATGCTACAAACCTATTGGAAAGCCTTAA
A_04_P054449CGGGCAAATCCCTACTACTCAGAAGTTGAGCTCAATTTCATCTCTGTTTTCTGGCCACAT
A_04_P083948TACACTGTGTTTACTCCACTCCTTAATCCTGTTGTGTACACTTTGAGGAATAAGGAGGTC
A_04_P099605ACAGCAAATTCACATACACAGTTCTGGAGGATGGCTGCTCTAAACATACTGGGGAATGGA
A_04_P033287TCTTTACAAGAGGAAACTGCAAGAAGGGGCCCAGCTGGAGATAGAGGACCACGTGGAGAA
A_04_P029302GCACATTTTATATGTGTTCCTTTTGTTCTAATCTTGTCAACCAGTACAAGTGACCAACTA
A_04_P061512AAGATGGTGACTCAATGCTGGAACATCTTCACCTTGAAAACAATTATATCAAAACTAGAG
A_04_P003721TGCAAGAACAGCGTAGCCTACATGGACCAACAGACCGGCAACCTCAAGAAGTCCCTGCTC
A_04_P013577GTACCATGAAATTGGAAGATCAATAGCAACTCTCATGACAGATGAGATTTTTCATGATGT
A_04_P053222GAGGTAAAGCCTTATCTACTTGTGCATCCCACTTTCTCTCCGTGTCTATATTCTATGGTT
A_04_P004432GAGAATCAGCTGATGGACAACCGCTTCCAACTTGTAAACGTCTGCTACAGTCCCGACTTT
A_04_P099604ACATACTGGGGAATGGAGCAAAACAGTCTTTGAATATAGAACACGCAAGGCTGTGAGACT
A_04_P097917ATGAATATTCTCATCCGGGAAATCCGCCTATCGCTTCAACAATTAGACCTGGGGTTGAAG
A_04_P067988TGTCGTTCAGGTAGCTCAGATTGTCAAAAATGAAATGGAAAATGCCATAAAACTTTCTGT
A_04_P080226CTACAGGTTCGAAACATCATTTTCTTTGGTTGTTGTGTATCCTGTTACTGATTCCAATAG
A_04_P005106ATACAAAACAAATAAGCCATCTCGTTTGCCCTTCCTTGATATTGCACCTTTGGACATCGG
A_04_P080223CAGGTTCGAAACATCATTTTCTTTGGTTGTTGTGTATCCTGTTACTGATTCCAATAGTTT
A_04_P075839TCTACTTGTACGTGACCAAAGTCCTTAAAGGAAAGAAGCTAAGCCTTCCAATGCCCATCT
A_04_P080225TACAGGTTCGAAACATCATTTTCTTTGGTTGTTGTGTATCCTGTTACTGATTCCAATAGT
A_04_P002113GGACAAGGCGACCGACTGAGCTCAGCTGCTTATTTATTGAAAATAAACAACACAAGAGTC
A_04_P075838CTACTTGTACGTGACCAAAGTCCTTAAAGGAAAGAAGCTAAGCCTTCCAATGCCCATCTG
A_04_P083155CAAAACCTATTGAAGTGTGTATGTACAGAGAACCATCACTACATGAAATTGGGGAAAAAC
A_04_P095802ATTGTCAGTTTCTTAGCAAGGTTGGGCTGTTCATCATGTCTGGACTATTTCACGACCCAG
A_04_P029967GTGGACGTTGGCCCAGTCTGTTTCAAATAAGTGAACTCCACCTAAATTAAAAAGAAAAGA
A_04_P051867TGTGATCTTTGGCTGTGAGGTGTTCGCCTACCCCATGGCCTCCATCGAGTGGAGAAAGGA
A_04_P005011AGAACTACAACATGTACATCTTCCCCGTGCACTGGCAATTCGGCCAGCTGGACCAGCACC
A_04_P007976TTGCTTCTCCAAGTACAAGTACTAGGTTGGCCATTTATAATATCTATTTGGTGCTAGTAA
A_04_P080222GGTTCGAAACATCATTTTCTTTGGTTGTTGTGTATCCTGTTACTGATTCCAATAGTTTTG
A_04_P005107TGGGGAAAGACAATCATTGAATACAAAACAAATAAGCCATCTCGTTTGCCCTTCCTTGAT
A_04_P092167TCAGATGACAATATTATGGAAACACTGCAGGGTCAGGTTTCAACAGCTCTAGGGGAAGCA
A_04_P016398GTTTGCCAATTCGGAACTTGAAAGGTTTGTTTCTGTCTCTGGATGAATCAAATTTCTTCC
A_04_P083153ATGAAATTGGGGAAAAACAAGGGCGTTCGAGGAAAAGCTCTGGAACACCAACTATGAATG
A_04_P005109GCAGGTTCACTTACACTGTTCTTGTCGATGGCTGCACGAAAAAGACAAATGAATGGGGAA
A_04_P033295CCAAGGATGCACTATGGATGCTATCAAAGTTTACTGTGATTTCTCTACTGGCGAAACCTG
A_04_P033296ACCAAGGATGCACTATGGATGCTATCAAAGTTTACTGTGATTTCTCTACTGGCGAAACCT
A_04_P033663GCCCTACATCTTCAGACACAAATGATCAGGATATGATCTTCTCTCTGTTTTACACTGTCA
A_04_P033294CAAGGATGCACTATGGATGCTATCAAAGTTTACTGTGATTTCTCTACTGGCGAAACCTGC
A_04_P033293AAGGATGCACTATGGATGCTATCAAAGTTTACTGTGATTTCTCTACTGGCGAAACCTGCA
A_04_P083152GAGGAAAAGCTCTGGAACACCAACTATGAATGGAGGCAAAGTCGTGAATCAAGACTCAAC
A_04_P034532ATGAAGGTGGCAATGAGGAGAATATTCAGCCAGCTGCTGTGTTTCCAGAAGTTGTTTTAA
A_04_P033292AGGATGCACTATGGATGCTATCAAAGTTTACTGTGATTTCTCTACTGGCGAAACCTGCAT
A_04_P041922TACATACGCTTCCAAACTCCTGAACCTGACAATCATTATGACTTTTGCCTCATACCGTGA
A_04_P041923TTACATACGCTTCCAAACTCCTGAACCTGACAATCATTATGACTTTTGCCTCATACCGTG
A_04_P083154TGTACAGAGAACCATCACTACATGAAATTGGGGAAAAACAAGGGCGTTCGAGGAAAAGCT
A_04_P100467AAACATTACCAGCTGGATTTAGGCTAACCACAACATCTGGGCAGTCACGGAAAATGACAG
A_04_P028651TGCAATTTTGGTCTCCGCCACATAACCATTCTGAAGCTTTTGGGTGTTGGAGAGGAAGTT
A_04_P005108CTTGTCGATGGCTGCACGAAAAAGACAAATGAATGGGGAAAGACAATCATTGAATACAAA
A_04_P036902TAATTCAGAGGCGTCAAGATGGCTCCGTGGACTTTGACCGGCCCTGGGAAGCTTACAAGG
A_04_P082732AGTGGTGAATATCAGTAGTTTGCAGGGTTTACAGGCTCTTGAAAACTGCAGCGAAGACCT
A_04_P080444ACTGATTGATGGCGAGTATAAGGATTACCTGGCATCTCATCCATTCGACACAGAGACAAC
A_04_P080443CTGATTGATGGCGAGTATAAGGATTACCTGGCATCTCATCCATTCGACACAGAGACAACT
A_04_P089937ACAAGCTGGACGTGGACATTTTGGCACAACTGAAATACACTGGGTGTGTCATTAAGGAGA
A_04_P000416TAGAAGAAAACCCCGTCGTGAAGACCCTCCTGGACGTCAACTGCCTGCTGTGCATCTGCT
A_04_P080445AACTGATTGATGGCGAGTATAAGGATTACCTGGCATCTCATCCATTCGACACAGAGACAA
A_04_P089787CAACAACAACTCCAAAGAAGAGAATTGGAACCTACACAAACATGAACAAGTAGAAAAACC
A_04_P069826TGCTGAACCATGGTATAAAGAAACCACTTACCAAAGAGACTATTCTCTGCCATTTTATAA
A_04_P080446AAACTGATTGATGGCGAGTATAAGGATTACCTGGCATCTCATCCATTCGACACAGAGACA
A_04_P098652TTGTCATCAATCCCAACTACGAGGTCTCCGAGTCCGATTACTCCAACAACATCATGAAGT
A_04_P057962AGTATGTGGAGTGCCTAGAAAAGAAAGTAGAGACTTTCACGTCGGAGAACAACGAGCTGT
A_04_P035452CTGTATTTGTAATTCCAGGTCAGTGGCTGGTGGACACCTCCATGATTTTATCCTCATGCT
A_04_P069053TCCGTGCATAGTTCTGACGAGAACATACCTGTGTCACATTTGTCTGAGAAAATTGTTTCA
A_04_P089791CACCAGTAAATCAAAGACTGAGTTGGGTGTTTCAAGAGTTAAATCTTTTCTTCCTGTTCC
A_04_P069822GAACCATGGTATAAAGAAACCACTTACCAAAGAGACTATTCTCTGCCATTTTATAAGCTT
A_04_P082177CTAACCAGAACTGAGAGACAGTTAATCCATGACTTTTATCACTTGGACTATTTGATGTTT
A_04_P071528GAAAATGTGAAGAGCTAAAGAAAAAACCTGGCACTTCGCTAGAGAGAACACCTGTTCCCA
A_04_P014266GGCCTCGGACGAGGCCATTGAGAAGCTGTCCACGCTGTACTGGTTTACCGTAGAATTTGG
A_04_P051042ATGCTGGTCGTGTACATTCGCTACCAGGACCAGACGGACGACGACGACGACGACGAGTGA
A_04_P002301AAGCTTTCGCAGAAAGGATACAGCTGGAGTCAGTTTAGTGATGTGGAAGAGAACAGGACT
A_04_P027306ATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGAGCTG
A_04_P068184CAAAAATCAATGAAATTCGCCAGATGTCTGGAGCTCAGATCAAAATTGCCAACGCCACTG
A_04_P068182AATCAATGAAATTCGCCAGATGTCTGGAGCTCAGATCAAAATTGCCAACGCCACTGAAGG
A_04_P068183AAATCAATGAAATTCGCCAGATGTCTGGAGCTCAGATCAAAATTGCCAACGCCACTGAAG
A_04_P040043GCCAGGGATAAAAGTATCAATGCCTTGAAATTGGCTTCAAGGAAACTAAAGAGAAACCAA
A_04_P027309TACATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGAG
A_04_P068186GACAAAAATCAATGAAATTCGCCAGATGTCTGGAGCTCAGATCAAAATTGCCAACGCCAC
A_04_P012977GTGCCTGGAACGGGAGTGACAGTGTCATCATGACCGGGGCTTACAACAACTTCTTCCGCA
A_04_P068185ACAAAAATCAATGAAATTCGCCAGATGTCTGGAGCTCAGATCAAAATTGCCAACGCCACT
A_04_P003912TTTATCTTCACCTTCTTCAAAGTTCCTGAGACCCGAGGCAGGACTTTTGAGGATATCACA
A_04_P027307CATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGAGCT
A_04_P074137GAAAATGAAGATGACAACGTTGTCTTAGCATTTGAACAACTGAGCGAAACCTTTTTTGAA
A_04_P074138GGAGCAGCTTATATATTATTGAAAGATTTTGCACTCACCATTAAAGCTATCAGTGTTTCC
A_04_P057689ACAAACTTTCAGGAACACAACTCTTACGGCAGAAATTCTCCAGCAGGTAATTCTTGGGTA
A_04_P040042TTAGACCTGGAAAGCTTGAGCCTCACGAGATTGGGCAAGCTGAAAGGAGAATTCAATGAA
A_04_P003626GTTGAGCAGCTGTTCGTTCCTGGTGGACAACCCCTACACCAACTCCTACTCCTACTCGTG
A_04_P027308ACATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGAGC
A_04_P027310CTACATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGA
A_04_P082358AAATGAGAAGATTTTCAGATGTGTCAGAACGTTCATTGGCTGTAAGGAACAAGGACAGAT
A_04_P003914TCTTTATCTTCACCTTCTTCAAAGTTCCTGAGACCCGAGGCAGGACTTTTGAGGATATCA
A_04_P048467ATTGTTTTTGAACTTGGTGTCACCTTTAATTACACCTTAGCAGATGGAACTGAAGTCAGT
A_04_P098422AAAGGATGATGACATCAGCAGACTCTTGAAATCGCTACCCAACTGGATTAACATGGCCCA
A_04_P101047TTAACATGGATGGTACAGCCCTTTATGAAGCGGTAGCTGCCATCTTTATAGCCCAAATGA
A_04_P003913CTTTATCTTCACCTTCTTCAAAGTTCCTGAGACCCGAGGCAGGACTTTTGAGGATATCAC
A_04_P050054TAACCCTGAAGCTGTAAATGAACCCAAGAAGAAGAAATATGCAAAAGAGGCTTGGCCGGG
A_04_P050055ATAACCCTGAAGCTGTAAATGAACCCAAGAAGAAGAAATATGCAAAAGAGGCTTGGCCGG
A_04_P002261TGACCCTTGACCTTTATCCTGAACCACAGCATATGCATGCCAGGCTGGGCACGAGGCTCA
A_04_P050056TATAACCCTGAAGCTGTAAATGAACCCAAGAAGAAGAAATATGCAAAAGAGGCTTGGCCG
A_04_P077452GGACTGCCTTTACCCACCAGACTAAAAGATTACTTGGAAGAATATAAATTCCAGGTATAA
A_04_P077456CTGGGGACTGCCTTTACCCACCAGACTAAAAGATTACTTGGAAGAATATAAATTCCAGGT
A_04_P077453GGGACTGCCTTTACCCACCAGACTAAAAGATTACTTGGAAGAATATAAATTCCAGGTATA
A_04_P002438TACTGAGAAACCAGGAACCGAAGAATCAATTGTAACTGAAGAGTTAATTGTAGTTACTTC
A_04_P003915TTCTTTATCTTCACCTTCTTCAAAGTTCCTGAGACCCGAGGCAGGACTTTTGAGGATATC
A_04_P002437GTATACTTTAGGACAATGCAGACAGTCTGAAAAAGAGAAAATGGAGCAAAAGGCCATTTC
A_04_P001796ACTCTACTATGACCAGGAGCGGAAGATGAACATGAAGGACAACGTCAGGCCGCTGCAGCG
A_04_P000366GCACAGTTACCCAAGATATTGGCAGGGATGGTGAAACCACTTCTCTTTCATAAAAAGTGA
A_04_P092835GACTAAGCGACACCAGAAATTCACCCATTTTTTACCCAGGCCAGTAGATCCTTCTAAGTT
A_04_P092832TAAGCGACACCAGAAATTCACCCATTTTTTACCCAGGCCAGTAGATCCTTCTAAGTTGCC
A_04_P092834ACTAAGCGACACCAGAAATTCACCCATTTTTTACCCAGGCCAGTAGATCCTTCTAAGTTG
A_04_P084832CAAGTCTTGCTTAGAAAATCAAGAGAAGCAGAATCCATGGCAACTCACCACCTTCCATGA
A_04_P092833CTAAGCGACACCAGAAATTCACCCATTTTTTACCCAGGCCAGTAGATCCTTCTAAGTTGC
A_04_P000367TTTATCCAGTCCCGGGCGCTGAGTGTTGAATTTCCAGAAATGATGTCTGAAGTTATTGCT
A_04_P095007AAGGTTAATTTAGCCAACGAGCCAAAGTACCGCCTGGACACAGTGAAAATTGAGGTCTAA
A_04_P059047TCTACTTCAACGTGGGCAAGCTGAAGCAGGAGATGGGTGGCATCGTGACCGAGATCATCC
A_04_P014040GCAGGAAAAGTACAAAAGCCAGATTTTGCATTTCGAAGAAGCCAAGGCCACCATCCATGA
A_04_P068197AAAGGCAAGAGGTTCACGTACAAGTTCAACTTCAGCAAGCTCATCGTGGTCAACTATCCT
A_04_P084833TTCAACCCCCTCAGCAGAACTATTCACTGGCTGAACTTGATGAGAAAATTAGTGCCCTCA
A_04_P084834TGGAAGGCATCTCTCCTGAATACTTTCAGTCTATAAACTTTTCTGGAAAAAGAAGAAAAG
A_04_P014038AGGAAAAGTACAAAAGCCAGATTTTGCATTTCGAAGAAGCCAAGGCCACCATCCATGAGA
A_04_P071088AGTTTCAAAGAGAACCTGAAGTGCTTTCTGTTTGTCATCCCCTTTAACTGCTGGGAGCCA
A_04_P003501TATCAACAGTGATGGGGCCATCAACTTCCAGGAGTTCCTCATACTGATTGTGAAGATAGG
A_04_P035696GTATGCCAAGAGGGCATTTCTGCACTGGTACATTCAAGAAGGCATGGAACAAGGAGAATT
A_04_P013130TCAGTACTCGAAGAAAAAGGATGCAGACTCTTGGTTCAAAGAGCTGGATATCAACAGTGA
A_04_P013126TACTCGAAGAAAAAGGATGCAGACTCTTGGTTCAAAGAGCTGGATATCAACAGTGACGGG
A_04_P003502ATATCAACAGTGATGGGGCCATCAACTTCCAGGAGTTCCTCATACTGATTGTGAAGATAG
A_04_P060934TTGCTAAAAGTCTGACCCCTAATAACACCATTAGAGAATGGCAAATTGTTTTCTGTATCG
A_04_P003503GATATCAACAGTGATGGGGCCATCAACTTCCAGGAGTTCCTCATACTGATTGTGAAGATA
A_04_P003505TGGATATCAACAGTGATGGGGCCATCAACTTCCAGGAGTTCCTCATACTGATTGTGAAGA
A_04_P003504GGATATCAACAGTGATGGGGCCATCAACTTCCAGGAGTTCCTCATACTGATTGTGAAGAT

POMC: Proopiomelanocortin, GalNAc-T6: UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6; FAM46A: Family with sequence similarity 46, member A; C. elegans: Caenorhabditis elegans; CRP: C-reactive protein; SLC17A5: Solute carrier family 17 (acidic sugar transporter), member 5; MRP-8: Macrophage migration inhibitory factor-related protein-8; KCNE2: Potassium voltage-gated channel, Isk-related family, member 2; PGR: Progesterone receptor; CA4: Carbonic anhydrase 4; STK17A: Serine/threonine kinase 17A; SOC2: Suppressor of cytokine signaling 2; PRKCZ: Protein kinase C, zeta; IFIT1B: Interferon-induced protein with tetratricopeptide repeats 1B; TE: TMEM30B: Transmembrane protein 30B; CTTNBP2: Cortactin binding protein 2; PTPRF: Protein tyrosine phosphatase, receptor type, f polypeptide; PPFIA2: Protein tyrosine phosphatase, receptor type, f polypeptide alpha 2; COL1A2: Collagen, Type I, alpha 2; BCL2L1: BCL2-like 1; SLC4A7: Solute carrier family 4, sodium bicarbonate cotransporter, member 7; GPX7: Glutathione peroxidase 7; LPXN: Leupaxin; PRLR: Prolactin receptor; O. cuniculus: Oryctolagus cuniculus; CSF: Colony stimulating factor; MMP: Matrix metallopeptidase.

Supplementary Table 2

Differentially expressed genes

Probe nameP (drug)FC ([M-T] vs. [M-C])Log FC ([M-T] vs. [M-C])FC (abs) ([M-T] vs. [M-C])Regulation ([M-T] vs. [M-C])Gene symbolDescription
A_04_P0902060.002592394−34.987576−5.12877134.987576DownBRINP3Bone morphogenetic protein/retinoic acid inducible neural-specific 3 (source: HGNC symbol; Acc.: 22393) (ENSOCUT00000011729)
A_04_P0870078.36E−045.1839492.37405165.183949UpNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0902040.013964647−35.64766−5.155735535.64766DownBRINP3Bone morphogenetic protein/retinoic acid inducible neural-specific 3 (source: HGNC symbol; Acc.: 22393) (ENSOCUT00000011729)
A_04_P0870100.0013535225.43377072.44195375.4337707UpNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0870080.0011620315.0778752.3442255.077875UpNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0870096.51E−046.18990662.62991766.1899066UpNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0902050.010273683−32.678364−5.03026432.678364DownBRINP3Bone morphogenetic protein/retinoic acid inducible neural-specific 3 (source: HGNC symbol; Acc.: 22393) (ENSOCUT00000011729)
A_04_P0870110.0013932985.3342612.41528845.334261UpNIM1KNIM1 serine/threonine protein kinase (source: HGNC symbol; Acc.: 28646) (ENSOCUT00000017806)
A_04_P0893491.41E−04−2.0694027−1.04921442.0694027DownCHRNA2Cholinergic receptor, nicotinic, alpha 2 (neuronal) (source: HGNC symbol; Acc.: 1956) (ENSOCUT00000007679)
A_04_P0005110.01476525618.5622254.21429818.562225UpRFT-IIO. cuniculus galactoside 2-L-fucosyltransferase (RFT-II), mRNA (NM_001082402)
A_04_P0957220.014857199−3.2431571−1.69739893.2431571DownMOB3BMOB kinase activator 3B (source: HGNC symbol; Acc.: 23825) (ENSOCUT00000017680)
A_04_P0005120.02924780711.2333613.489717711.233361UpRFT-IIO. cuniculus galactoside 2-L-fucosyltransferase (RFT-II), mRNA (NM_001082402)
A_04_P0613676.82E−042.03939−1.02813772.03939DownTPK1Thiamin pyrophosphokinase 1 (source: HGNC symbol; Acc.: 17358) (ENSOCUT00000003405)
A_04_P0449951.77E−04−2.0282369−1.02022612.0282369DownLOC100346337Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1U4C5) (ENSOCUT00000026037)
A_04_P0395234.39E−05−2.037557−1.02684032.037557DownLOC100346673Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1TUR2) (ENSOCUT00000024312)
A_04_P0957260.002862763−3.7613301−1.9112433.7613301DownMOB3BMOB kinase activator 3B (source: HGNC symbol; Acc.: 23825) (ENSOCUT00000017680)
A_04_P0005140.0448028339.4087543.23400389.408754UpRFT-IIO. cuniculus galactoside 2-L-fucosyltransferase (RFT-II), mRNA (NM_001082402)
A_04_P0035940.003417118−2.465992−1.30216812.465992DownLOC100009480O. cuniculus lipophilin CS (LOC100009480), mRNA (NM_001082723)
A_04_P0815030.022404155−17.285624−4.111500717.285624DownGRIA2Glutamate receptor, ionotropic, AMPA 2 (source: HGNC symbol; Acc.: 4572) (ENSOCUT00000026179)
A_04_P0021460.0166256583.28630831.71646793.2863083UpNOS3O. cuniculus nitric oxide synthase 3 (endothelial cell) (NOS3), mRNA (NM_001082733)
A_04_P0957230.011801046−2.7260911−1.44683382.7260911DownMOB3BMOB kinase activator 3B (source: HGNC symbol; Acc.: 23825) (ENSOCUT00000017680)
A_04_P0957240.037129164−2.9672625−1.56913262.9672625DownMOB3BMOB kinase activator 3B (source: HGNC symbol; Acc.: 23825) (ENSOCUT00000017680)
A_04_P0615193.86E−04−2.0915723−1.06458782.0915723DownTMPRSS12Transmembrane (C-terminal) protease, serine 12 (source: HGNC symbol; Acc.: 28779) (ENSOCUT00000012143)
A_04_P0005150.02894154211.7391633.553257711.739163UpRFT-IIO. cuniculus galactoside 2-L-fucosyltransferase (RFT-II), mRNA (NM_001082402)
A_04_P0083210.0044623682.15476231.10752872.1547623UpCTSFCathepsin F (source: HGNC symbol; Acc.: 2531) (ENSOCUT00000013703)
A_04_P0273080.015789868−8.41193−3.07243688.41193DownVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T4R1) (ENSOCUT00000013108)
A_04_P0898200.0087678772.86759281.51984022.8675928UpTMEM81Transmembrane protein 81 (source: HGNC symbol; Acc.: 32349) (ENSOCUT00000015420)
A_04_P0197310.0146665282.13102561.0915482.1310256UpDSTPredicted: O. cuniculus dystonin (LOC100345428), miscRNA (XR_085126)
A_04_P0519575.14E−05−2.0692248−1.04909042.0692248DownSSTR2Somatostatin receptor 2 (source: HGNC symbol; Acc.: 11331) (ENSOCUT00000009346)
A_04_P0779471.37E-04−2.1267912−1.08867842.1267912DownPLEKHG6Pleckstrin homology domain containing, family G (with Rho GEF domain) member 6 (source: HGNC symbol; Acc.: 25562) (ENSOCUT00000010134)
A_04_P0273100.016151104−7.2762876−2.86320267.2762876DownVIPR1Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T4R1) (ENSOCUT00000013108)
A_04_P0991270.033585192.19445751.13386442.1944575UpDSTPredicted: O. cuniculus dystonin (LOC100345428), miscRNA (XR_085126)
A_04_P0334120.0365826673.4685561.79433513.468556UpCCNE1Cyclin E1 (source: HGNC symbol; Acc.: 1589) (ENSOCUT00000009147)
A_04_P0674840.031035315−2.4192803−1.27457792.4192803DownGPRC5DG protein-coupled receptor, family C, group 5, member D (source: HGNC symbol; Acc.: 13310) (ENSOCUT00000015334)
A_04_P0957250.013923194−2.5073705−1.32617522.5073705DownMOB3BMOB kinase activator 3B (source: HGNC symbol; Acc.: 23825) (ENSOCUT00000017680)
A_04_P0724270.0029858399.5818653.26030669.581865UpERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc: 26495) (ENSOCUT00000006001)
A_04_P0803610.006089133−3.159741−1.65980633.159741DownLOC100346813
A_04_P0870840.0165228282.08526421.06023032.0852642UpHECTD2HECT domain containing E3 ubiquitin protein ligase 2 (source: HGNC symbol; Acc.: 26736) (ENSOCUT00000015038)
A_04_P0501630.0248473754.9617952.3108624.961795UpOTCOrnithine carbamoyltransferase (source: HGNC symbol; Acc.: 8512) (ENSOCUT00000025516)
A_04_P0042910.004282892.39387371.2593472.3938737UpPPICPeptidylprolyl isomerase C (cyclophilin C) (source: HGNC symbol; Acc.: 9256) (ENSOCUT00000012051)
A_04_P0679770.023129197−2.4537835−1.2950082.4537835DownKRT75Keratin 75 (source: HGNC symbol; Acc.: 24431) (ENSOCUT00000002625)
A_04_P0721974.02E−05−2.014058−1.01010542.014058DownSLC13A5Solute carrier family 13 (sodium-dependent citrate transporter), member 5 (source: HGNC symbol; Acc.: 23089) (ENSOCUT00000009882)
A_04_P0426870.018582681−3.9991665−1.99969943.9991665DownCCL24Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1SCU3) (ENSOCUT00000000207)
A_04_P1024670.04062720817.0938974.095409417.093897UpUPK1BUroplakin 1B (source: HGNC symbol; Acc.: 12578) (ENSOCUT00000008290)
A_04_P0724300.0076019734.64998962.21722754.6499896UpERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0050440.0089995952.17670061.12214292.1767006UpNRG1Neuregulin 1 (source: HGNC symbol; Acc.: 7997) (ENSOCUT00000005836)
A_04_P0737070.013036333−2.2599533−1.17629292.2599533DownACEO. cuniculus ACE, transcript variant 2, mRNA (NM_001171069)
A_04_P0015760.0231325252.35102081.23328732.3510208UpPRLRO. cuniculus PRLR, mRNA (NM_001082231)
A_04_P0022610.01926593−3.3654182−1.75078583.3654182DownPRKCZO. cuniculus PRKCZ, mRNA (NM_001082758)
A_04_P0674670.02113763.96575161.98759443.9657516UpHDXHighly divergent homeobox (source: HGNC symbol; Acc.: 26411) (ENSOCUT00000000902)
A_04_P0501620.0289480164.54074672.18292954.5407467UpOTCOrnithine carbamoyltransferase (source: HGNC symbol; Acc.: 8512) (ENSOCUT00000025516)
A_04_P0724280.003700546.57618672.71725136.5761867UpERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0724310.0072552665.62381462.4915495.6238146UpERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0683480.009709035−2.018818−1.01351072.018818DownTNFSF8Tumor necrosis factor (ligand) superfamily, member 8 (source: HGNC symbol; Acc.: 11938) (ENSOCUT00000009975)
A_04_P0130320.041744873−3.750062−1.90691453.750062DownLBPO. cuniculus LBP, mRNA (NM_001195719)
A_04_P0606080.019984773.59622881.84648483.5962288UpALDH1L2Aldehyde dehydrogenase 1 family, member L2 (source: HGNC symbol; Acc.: 26777) (ENSOCUT00000006965)
A_04_P0886840.0299216943.06024671.61364793.0602467UpNUF2NUF2, NDC80 kinetochore complex component (source: HGNC symbol; Acc.: 14621) (ENSOCUT00000001171)
A_04_P0961670.02870236−2.2684171−1.18168592.2684171DownTMEFF2Transmembrane protein with EGF-like and two follistatin-like domains 2 (source: HGNC symbol; Acc.: 11867) (ENSOCUT00000017723)
A_04_P0460430.0309086672.0803661.05683732.080366UpOLFR651_1O. cuniculus olfactory receptor 651 (OLFR651_1), mRNA (NM_001171473)
A_04_P0724290.0099099395.43658922.44270185.4365892UpERP27Endoplasmic reticulum protein 27 (source: HGNC symbol; Acc.: 26495) (ENSOCUT00000006001)
A_04_P0884070.028551526−2.1645124−1.1140422.1645124DownSLC7A8O. cuniculus solute carrier family 7 (amino acid transporter light chain, L system), member 8 (SLC7A8), mRNA (NM_001082682)
A_04_P0757000.034938697−2.0471556−1.03362082.0471556DownTYMSThymidylate synthetase (source: HGNC symbol; Acc.: 12441) (ENSOCUT00000008664)
A_04_P0628482.81E−04−2.7127166−1.43973832.7127166DownCREMcAMP responsive element modulator (source: HGNC symbol; Acc.: 2352) (ENSOCUT00000001657)
A_04_P0690250.036677245−2.6477945−1.40479112.6477945DownFAM150AFamily with sequence similarity 150, member A (source: HGNC symbol; Acc.: 33775) (ENSOCUT00000033417)
A_04_P0663170.0257795232.35800891.23756912.3580089UpVASH1Vasohibin 1 (source: HGNC symbol; Acc.: 19964) (ENSOCUT00000009526)
A_04_P0129810.001837161−2.371969−1.24608522.371969DownTGFATransforming growth factor, alpha (source: HGNC symbol; Acc.: 11765) (ENSOCUT00000033653)
A_04_P0625930.0142800572.28265671.19071392.2826567UpLOC100353757Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1SJJ6) (ENSOCUT00000003365)
A_04_P0756970.032748736−2.02286−1.01639652.02286DownTYMSThymidylate synthetase (source: HGNC symbol; Acc.: 12441) (ENSOCUT00000008664)
A_04_P0563820.03879594−2.1264076−1.08841822.1264076DownITGAXIntegrin, alpha X (complement component 3 receptor 4 subunit) (source: HGNC symbol; Acc.: 6152) (ENSOCUT00000017426)
A_04_P0756990.0334667−2.014203−1.01020912.014203DownTYMSThymidylate synthetase (source: HGNC symbol; Acc.: 12441) (ENSOCUT00000008664)
A_04_P0750470.032421623.64015131.86399843.6401513UpB3GALNT1Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) (source: HGNC symbol; Acc.: 918) (ENSOCUT00000001174)
A_04_P0648480.006981436−2.088532−1.06248932.088532DownIL12BInterleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) (source: HGNC symbol; Acc.: 5970) (ENSOCUT00000016318)
A_04_P0806000.0398671633.1401031.65081193.140103UpEYSPredicted: O. cuniculus eyes shut homolog (Drosophila) (EYS), mRNA (XM_008263282)
A_04_P0499420.0163678588.1231023.02203088.123102UpADAD1Adenosine deaminase domain containing 1 (testis-specific) (source: HGNC symbol; Acc.: 30713) (ENSOCUT00000012988)
A_04_P0139654.85E−05−2.376971−1.24912432.376971DownHTR3B5-hydroxytryptamine (serotonin) receptor 3B, ionotropic (source: HGNC symbol; Acc.: 5298) (ENSOCUT00000033424)
A_04_P0796240.0470044652.22687461.15502022.2268746UpRIC8BRIC8 GEFB (source: HGNC symbol; Acc.: 25555) (ENSOCUT00000006126)
A_04_P0428770.013875492−2.0739286−1.05236632.0739286DownHIF3APredicted: O. cuniculus hypoxia inducible factor 3, alpha subunit (HIF3A), mRNA (XM_008252146)
A_04_P0404170.028284287−2.9792025−1.57492612.9792025DownBPIFA3BPI fold containing family A, member 3 (source: HGNC symbol; Acc.: 16204) (ENSOCUT00000015715)
A_04_P0624780.0144906452.43852021.2860062.4385202UpLOC100349425Predicted: O. cuniculus exocyst complex component 1-like (LOC100349425), mRNA (XM_002717166)
A_04_P0544490.002579865−2.1617088−1.11217222.1617088DownMMP1O. cuniculus matrix metallopeptidase 1 (interstitial collagenase) (MMP1), mRNA (NM_001171139)
A_04_P0050940.009245173−2.4121513−1.27032042.4121513DownCER1Cerberus 1, DAN family BMP antagonist (source: HGNC symbol; Acc.: 1862) (ENSOCUT00000010373)
A_04_P0886830.0192006553.60196921.84878593.6019692UpNUF2NUF2, NDC80 kinetochore complex component (source: HGNC symbol; Acc.: 14621) (ENSOCUT00000001171)
A_04_P0130870.008903244−2.3892436−1.25655392.3892436DownCYP19A1CYP19A1, mRNA (source: RefSeq mRNA; Acc.: NM_001170921) (ENSOCUT00000012304)
A_04_P0750490.0377946873.64558151.8661493.6455815UpB3GALNT1Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) (source: HGNC symbol; Acc.: 918) (ENSOCUT00000001174)
A_04_P0477670.043420472.09738281.06859022.0973828UpGCH1GTP cyclohydrolase 1 (source: HGNC symbol; Acc.: 4193) (ENSOCUT00000003056)
A_04_P0750480.0292529844.0148852.00535874.014885UpB3GALNT1Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) (source: HGNC symbol; Acc.: 918) (ENSOCUT00000001174)
A_04_P0871720.048340406−2.159121−1.11044412.159121DownARHGEF38Rho GEF 38 (source: HGNC symbol; Acc.: 25968) (ENSOCUT00000008875)
A_04_P0699770.008163161−2.248162−1.1687462.248162DownTREML1Triggering receptor expressed on myeloid cells-like 1 (source: HGNC symbol; Acc.: 20434) (ENSOCUT00000007264)
A_04_P0870820.029622162.02313281.01659112.0231328UpHECTD2HECT domain containing E3 ubiquitin protein ligase 2 (source: HGNC symbol; Acc.: 26736) (ENSOCUT00000015038)
A_04_P0861010.0089581332.28657721.19318962.2865772UpSPATS1Spermatogenesis associated, serine-rich 1 (source: HGNC symbol; Acc.: 22957) (ENSOCUT00000017228)
A_04_P1018770.038377283.03598621.60216523.0359862UpITGBL1Integrin, beta-like 1 (with EGF-like repeat domains) (source: HGNC symbol; Acc.: 6164) (ENSOCUT00000008813)
A_04_P0980650.02010309−2.2379515−1.16217882.2379515DownLRRD1Leucine-rich repeats and death domain containing 1 (source: HGNC symbol; Acc.: 34300) (ENSOCUT00000004562)
A_04_P0200520.033614933−3.511037−1.81189733.511037DownLRRN1Predicted: O. cuniculus leucine rich repeat protein 1, neuronal-like (LOC100344514), mRNA (XM_002720615)
A_04_P0184210.0089126882.18487881.12755322.1848788UpGNGT1Guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1 (source: HGNC symbol; Acc.: 4411) (ENSOCUT00000017033)
A_04_P0576770.0182536−2.1814566−1.12529182.1814566DownSLC34A2Solute carrier family 34 (Type II sodium/phosphate contransporter), member 2 (source: HGNC symbol; Acc.: 11020) (ENSOCUT00000002945)
A_04_P1018790.0399960472.76490121.46722792.7649012UpITGBL1Integrin, beta-like 1 (with EGF-like repeat domains) (source: HGNC symbol; Acc.: 6164) (ENSOCUT00000008813)
A_04_P0045760.03667116514.2571023.833608914.257102UpMYH1O. cuniculus myosin, heavy chain 1, skeletal muscle, adult (MYH1), mRNA (NM_001109816)
A_04_P0555250.001051425−2.5741715−1.36410822.5741715DownTMEM176BTransmembrane protein 176B (source: HGNC symbol; Acc.: 29596) (ENSOCUT00000016892)
A_04_P0051210.00654842−2.6257641−1.39273742.6257641DownHTR3B5-hydroxytryptamine (serotonin) receptor 3B, ionotropic (source: HGNC symbol; Acc.: 5298) (ENSOCUT00000033424)
A_04_P0707870.02381212.67237641.41812322.6723764UpDTLDenticleless E3 ubiquitin protein ligase homolog (Drosophila) (source: HGNC symbol; Acc.: 30288) (ENSOCUT00000000436)
A_04_P0031822.57E−043.09898831.63179733.0989883UpCGAO. cuniculus glycoprotein hormones, alpha polypeptide (CGA), mRNA (NM_001082724)
A_04_P0703440.0213182573.8014741.9265593.801474UpLECT2Leukocyte cell-derived chemotaxin 2 (source: HGNC symbol; Acc.: 6550) (ENSOCUT00000006379)
A_04_P0477680.0377559182.08047371.0569122.0804737UpGCH1GTP cyclohydrolase 1 (source: HGNC symbol; Acc.: 4193) (ENSOCUT00000003056)
A_04_P0063690.009818262−2.6181357−1.38853992.6181357DownWIPI1WD repeat domain, phosphoinositide interacting 1 (source: HGNC symbol; Acc.: 25471) (ENSOCUT00000017410)
A_04_P0624810.0384619242.44626381.290582.4462638UpLOC100349425Predicted: O. cuniculus exocyst complex component 1-like (LOC100349425), mRNA (XM_002717166)
A_04_P0477710.038790932.08671361.06123262.0867136UpGCH1GTP cyclohydrolase 1 (source: HGNC symbol; Acc.: 4193) (ENSOCUT00000003056)
A_04_P0130340.026828822−3.5224009−1.81655913.5224009DownLBPO. cuniculus LBP, mRNA (NM_001195719)
A_04_P1015150.0096378952.4760381.30803352.476038UpCTNNA2Catenin (cadherin-associated protein), alpha 2 (source: HGNC symbol; Acc.: 2510) (ENSOCUT00000033690)
A_04_P0860970.021286663.68584081.88199383.6858408UpSPATS1Spermatogenesis associated, serine-rich 1 (source: HGNC symbol; Acc.: 22957) (ENSOCUT00000017228)
A_04_P0721870.0275342352.458751.2979252.45875UpGEMGTP binding protein overexpressed in skeletal muscle (source: HGNC symbol; Acc.: 4234) (ENSOCUT00000001030)
A_04_P1018800.0421398022.77615171.47308642.7761517UpITGBL1Integrin, beta-like 1 (with EGF-like repeat domains) (source: HGNC symbol; Acc.: 6164) (ENSOCUT00000008813)
A_04_P0129610.0258341362.30934361.20748282.3093436UpACE-1O. cuniculus acetylcholinesterase mRNA, partial cds (U05036)
A_04_P0627620.017634036−2.2404964−1.16381842.2404964DownEPHA8EPH receptor A8 (source: HGNC symbol; Acc.: 3391) (ENSOCUT00000015118)
A_04_P0043860.0393849722.17043161.11798192.1704316UpTIMP4O. cuniculus TIMP metallopeptidase inhibitor 4 (TIMP4), mRNA (NM_001195690)
A_04_P0793120.0285801465.57939862.48010975.5793986UpNR4A3Nuclear receptor subfamily 4, group A, member 3 (source: HGNC symbol; Acc: 7982) (ENSOCUT00000000737)
A_04_P0477700.0192252572.05684691.04043442.0568469UpGCH1GTP cyclohydrolase 1 (source: HGNC symbol; Acc.: 4193) (ENSOCUT00000003056)
A_04_P0721880.029215532.31601881.2116472.3160188UpGEMGTP binding protein overexpressed in skeletal muscle (source: HGNC symbol;Acc.: 4234) (ENSOCUT00000001030)
A_04_P0347870.037558276−2.7561917−1.46267632.7561917DownLOC100351425Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1T522) (ENSOCUT00000013261)
A_04_P0848320.011172667−2.3737729−1.24718192.3737729DownMBIPMAP3K12 binding inhibitory protein 1 (source: HGNC symbol; Acc.: 20427) (ENSOCUT00000017089)
A_04_P0503760.001221032−2.6195357−1.38931112.6195357DownODF4Outer dense fiber of sperm tails 4 (source: HGNC symbol; Acc.: 19056) (ENSOCUT00000015082)
A_04_P0163990.02350145−2.692988−1.42920782.692988DownFKBP1Bnbc39d02.x1 Rabbit trigeminal nerve. Unnormalized (nbc) O. cuniculus cDNA clone nbc39d02 3’, mRNA sequence (EB378230)
A_04_P0646170.001882354−2.809861−1.49049882.809861DownHUNKhormonally up-regulated Neu-associated kinase (source: HGNC symbol; Acc: 13326) (ENSOCUT00000005095)
A_04_P0130350.02182632−3.7424948−1.90400033.7424948DownLBPO. cuniculus LBP, mRNA (NM_001195719)
A_04_P0573802.48E−04−2.2619977−1.17759752.2619977DownC12H6orf52Predicted: O. cuniculus chromosome 12 open reading frame, human C6orf52 (C12H6orf52), mRNA (XM_008262518)
A_04_P0870520.03150471−2.5041976−1.32434842.5041976DownCITED1Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1 (source: HGNC symbol; Acc.: 1986) (ENSOCUT00000013306)
A_04_P0345320.004731383−2.0362408−1.02590812.0362408DownLOC100355813Predicted: O. cuniculus putative olfactory receptor GPCRLTM7 (LOC100355813), mRNA (XM_008269585)
A_04_P0984320.0068389332.52113531.33407352.5211353UpUGGT2Predicted: O. cuniculus UGGT2, mRNA (XM_008260110)
A_04_P0796220.040481892.4530921.29460142.453092UpRIC8BPredicted: O. cuniculus RIC8 GEFB (RIC8B), transcript variant X4, mRNA (XM_008257114)
A_04_P0866740.0356223772.76925541.46949822.7692554UpARHGAP11APredicted: O. cuniculus Rho GTPase ARHGAP11A, transcript variant X1, mRNA (XM_008269248)
A_04_P0653780.0328358044.45989752.15701064.4598975UpELOVL2ELOVL fatty acid elongase 2 (source: HGNC symbol; Acc.: 14416) (ENSOCUT00000013015)
A_04_P0802670.0376965932.04738471.03378222.0473847UpHTR2B5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled (source: HGNC symbol; Acc.: 5294) (ENSOCUT00000008577)
A_04_P0015193.12E−04−2.1444156−1.10058452.1444156DownLPHO. cuniculus LPH, mRNA (NM_001101689)
A_04_P0018680.03393962.5017161.32291792.501716UpADH1AO. cuniculus alcohol dehydrogenase 1A (class I), alpha polypeptide (ADH1A), mRNA (NM_001101704)
A_04_P0692590.012302654−2.1960154−1.13488822.1960154DownSLC26A4Solute carrier family 26 (anion exchanger), member 4 (source: HGNC symbol; Acc.: 8818) (ENSOCUT00000012637)
A_04_P0848330.008474713−2.0781624−1.05530832.0781624DownMBIPMAP3K12 binding inhibitory protein 1 (source: HGNC symbol; Acc.: 20427) (ENSOCUT00000017089)
A_04_P0887070.031126112−2.180206−1.12446452.180206DownCLEC1AC-type lectin domain family 1, member A (source: HGNC symbol; Acc.: 24355) (ENSOCUT00000016787)
A_04_P0848340.008935675−2.0264857−1.018982.0264857DownMBIPMAP3K12 binding inhibitory protein 1 (source: HGNC symbol; Acc.: 20427) (ENSOCUT00000017089)
A_04_P0902690.0411802464.9452382.306044.945238UpSH3GL2SH3-domain GRB2-like 2 (source: HGNC symbol; Acc.: 10831) (ENSOCUT00000001181)
A_04_P0023430.042952962.1915671.13196282.191567UpFKBP1BO. cuniculus FKBP1B, 12.6 kDa, mRNA (NM_001082145)
A_04_P0926100.003830259−2.5908234−1.37341072.5908234DownPPP3R2Predicted: O. cuniculus protein phosphatase 3, regulatory subunit B, beta (PPP3R2), transcript variant X1, mRNA (XM_002708148)
A_04_P0995070.037753712−2.3505616−1.23300552.3505616DownAIM1Absent in melanoma 1 (source: HGNC symbol; Acc.: 356) (ENSOCUT00000013372)
A_04_P0470020.025010375.109432.35316235.10943UpASRGL1Asparaginase like 1 (source: HGNC symbol; Acc.: 16448) (ENSOCUT00000005922)
A_04_P0814090.043412738−2.7950842−1.48289182.7950842DownCNPY1Canopy FGF signaling regulator 1 (source: HGNC symbol; Acc.: 27786) (ENSOCUT00000002453)
A_04_P0335630.002682326−3.0705657−1.61850453.0705657DownLOC100144334Uncharacterized protein (source: UniProtKB/TrEMBL; Acc.: G1SR31) (ENSOCUT00000006477)
A_04_P0317510.0033510422.47377351.30671332.4737735UpATP2A1O. cuniculus ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 (ATP2A1), mRNA (NM_001089318)
A_04_P0847520.049759754.12122772.04307414.1212277UpGRIA3Glutamate receptor, ionotropic, AMPA 3 (source: HGNC symbol; Acc.: 4573) (ENSOCUT00000000315)
A_04_P0674830.027998285−2.0428982−1.03061722.0428982DownGPRC5DG protein-coupled receptor, family C, group 5, member D (source: HGNC symbol; Acc.: 13310) (ENSOCUT00000015334)
A_04_P0657480.026877979−2.5302963−1.33930642.5302963DownLOC100337897Chromosome 3 open reading frame 20 (source: HGNC symbol; Acc.: 25320) (ENSOCUT00000030393)
A_04_P0036013.92E−04−2.5369635−1.34310272.5369635DownRAG2O. cuniculus RAG2, mRNA (NM_001171141)
A_04_P0610730.0342384872.2327921.15884882.232792UpGPR155G protein-coupled receptor 155 (source: HGNC symbol; Acc.: 22951) (ENSOCUT00000003686)
A_04_P0766970.042428083.97156141.98970633.9715614UpCLCA1Chloride channel accessory 1 (source: HGNC symbol; Acc.: 2015) (ENSOCUT00000004738)


Probe nameSequence

A_04_P090206GCAGGCGTTTAATGCCAAATTGCCAAACACCATGGATTACGACACGACCAAATTATGTAG
A_04_P087007AAGAAAGGGTCCCGTGTCTACAGGGGCATAAGACACACGTCCAAATTTTGTTCAATTTTA
A_04_P090204AGGCGTTTAATGCCAAATTGCCAAACACCATGGATTACGACACGACCAAATTATGTAGTT
A_04_P087010AAGGGAAAGATGCTCGAAGCTCAATCACAGGGGTCTATAGAATCATTTTACATAGAGTCC
A_04_P087008AATCATTTTACATAGAGTCCAGAGGAAAAAGGCTTCGGAGAGTGGCCCAGTAATGATGCT
A_04_P087009TCAATCACAGGGGTCTATAGAATCATTTTACATAGAGTCCAGAGGAAAAAGGCTTCGGAG
A_04_P090205CAGGCGTTTAATGCCAAATTGCCAAACACCATGGATTACGACACGACCAAATTATGTAGT
A_04_P087011AGAACACATTCGAAATAATCAAGGGAAAGATGCTCGAAGCTCAATCACAGGGGTCTATAG
A_04_P089349AAGACTGGAAGTATGTCGCCATGGTCATCGACAGGATATTCCTCTGGCTGTTTATTATCG
A_04_P000511TAAAAATAATTCAGAACTGACCTCAGCGGCGACTGGGGGAACTTGACAAGTACGTTCACA
A_04_P095722ACAAACACTTCTATTACTTCGTCACAGAGATGAACCTCATAGACCGCAAGGAGCTAGAGC
A_04_P000512ATAAAAATAATTCAGAACTGACCTCAGCGGCGACTGGGGGAACTTGACAAGTACGTTCAC
A_04_P061367AAGAACAAATTGTGTGTAGACACTGGAATGGAAGGAGACTGGTGTGGCCTTATTCCCGTT
A_04_P044995TGCAGTGCCCATCTTGTTGCAATTTTGTGTGTTTATGGGCCAATCATCATCATCTATCTA
A_04_P039523TTATTTTATGGAACAGGCCTTGGAGTTTATCTCAGTTCAACTTTCTCACTTTCTCCGGGG
A_04_P095726TGCTACAAACACTTCTATTACTTCGTCACAGAGATGAACCTCATAGACCGCAAGGAGCTA
A_04_P000514AAATAAAAATAATTCAGAACTGACCTCAGCGGCGACTGGGGGAACTTGACAAGTACGTTC
A_04_P003594GAATTCAAAAACTGTTTTCTCTCACAGTCTGAGGAGACCCTGAGAAATGTTGTGGAGATG
A_04_P081503TACAAGTCAAGGGCCGAGGCGAAACGAATGAAGGTGGCAAAGAATGCACAGAATATTAAC
A_04_P002146TTTTCGGGCTCACGCTGCGCACCCAGGAGGTGACAAGCCGCATACGCACCCAGAGTTTCT
A_04_P095723TACAAACACTTCTATTACTTCGTCACAGAGATGAACCTCATAGACCGCAAGGAGCTAGAG
A_04_P095724CTACAAACACTTCTATTACTTCGTCACAGAGATGAACCTCATAGACCGCAAGGAGCTAGA
A_04_P061519TATGGAAATGGCTGTGGTCGAAGAAATTTTCCTGGTGTCTATATTGCGCCATCCTTCTAT
A_04_P000515GAAAATAAAAATAATTCAGAACTGACCTCAGCGGCGACTGGGGGAACTTGACAAGTACGT
A_04_P008321AAGGTCTACATCAATGACTCGGTGGAGCTGAGCCAGAATGAGCAAAAGCTGGCGGCCTGG
A_04_P027308ACATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGAGC
A_04_P089820TTGGTGAACCTGAATTTCCATCAGTCCCTTACTGATGATCAGAAATTAGTGGCTGAGGGC
A_04_P019731CAATTTTGCTTGCAGAAAGCTCTGAAATAAAACATGTCCCTTAACTACATTGCTATGGAA
A_04_P051957TCTTATCTGACAACTTCAAGAAGAGCTTCCAGAATGTCCTGTGCTTGGTCAAAGTGAGCG
A_04_P077947TAATGCCCTCATTGTGCACTGCGCCTGTCCAACAACTCGTGCCCGATGGCTGCAGAAGAT
A_04_P027310CTACATCATGTTCGCCTTCTTCCCTGACAACTTCAAGGCTGAAGTGAAAATGGTCTTTGA
A_04_P099127CCTTCGAAGATCCCCACGCCCCAGAGGAAATCACCTGCCAGCAAGTCCTCAAAGAGATAG
A_04_P033412TGGATGGTTCCATTTGCCATGGTTATAAGAGAGACAGGAAGCTCCAAACTGAAGCACTTC
A_04_P067484TGAGGAGGATGTAGCATTAACTTCATATGGTACTCCCATTCAGCTGCAGACTGTTGATCC
A_04_P095725GCTACAAACACTTCTATTACTTCGTCACAGAGATGAACCTCATAGACCGCAAGGAGCTAG
A_04_P072427TTCCTAGAAGGGAAACTGTTGAGAGAAAATCATGAATCAGAAGAAAAGACTCCAAAGGTG
A_04_P080361TCTGTTCCAGCACGTGGGCATACACTCGTCACTCCTTGGGAAAGAACAATATTTCAAAGT
A_04_P087084ACAGGAAGTGACAGAGTACCTGTAGGAGGAATGGCAGATTTGAACTTCAAAATTTCAAAA
A_04_P050163AAGCCAGAAGAAGTGGACGATGAAGTGTTCTATTCTCCACGATCACTAGTATTCCCAGAG
A_04_P004291ATATGGATACAAGGGAAGCAGCTTTCATCGGGTCATCAAGGATTTCATGATCCAAGGAGG
A_04_P067977GGCTCCAGCGTCAAGTTTGTCTCCACGACATCATCCAGCCGCAAGAGCTATAGGCACTAA
A_04_P072197ACAGGACTGATGATGAACATAATTGGAGTCTTGTGTGTGTTTTTGGCGGTCAACACCTGG
A_04_P042687TTCCTAAGAAGATCCCTGAGAGCCAAGTGGTGAGCTACCAGCTGTCCAGCGGGAGTGTCT
A_04_P102467TTTATAGTGTACGGCTTTGAAGTGGCATCTTGTATCACAGCTGCAACACAACGAGACTTT
A_04_P072430TTGACGATTTATCGAACTCTAGATGATGAGTGGGATGCACTGCCCATTACAGAAGTTTCA
A_04_P005044ATTTCGGAAAGCCACTCTGTAATCATGATGTCATCAGTAGAAAACAGTAGGCACAGCAGC
A_04_P073707TCTCAAGGTGACTTTGATCCAGGGGCCAAGTTCCACATCCCTTCAAGTGTGCCTTACATC
A_04_P001576AACAACATCCTGGTGTTAGTGCAAGATCCAGGAGCTCAAAACGTGGCTTTGTTTGAAGAG
A_04_P002261TGACCCTTGACCTTTATCCTGAACCACAGCATATGCATGCCAGGCTGGGCACGAGGCTCA
A_04_P067467GATGATACCTCATTCAGTGTGTCTTCTTTATCAGAGAAAAACGCCTCAGACAGTTTGTGA
A_04_P050162GTGTTCTATTCTCCACGATCACTAGTATTCCCAGAGGCAGAAAACAGAAAGTGGACAATC
A_04_P072428ATTGAGCATGTGCAAAACTTTTATGATGGATTCCTAGAAGGGAAACTGTTGAGAGAAAAT
A_04_P072431TTCAAACTGAAGAAGTCTCAGCTACCAGCTTTGACGATTTATCGAACTCTAGATGATGAG
A_04_P068348TGGTAGACAAATTCCAGTATGTGGATACCAACACCTTTCCTCTTGAAAATGTGCTGTCTA
A_04_P013032GGATTCAATGTGGAGCTGTTGGAAGCTCTCCTCAACTACTACATTCTCAACAACCTCTAC
A_04_P060608TGTTCACAAGGGACATAAACAAAGCCATGTATGTGAGTGAGAAACTAGAAGCAGGAACTG
A_04_P088684CAACAACTAAAAGATGCCACCGAAAGGGAGAAACTGAAGTCTCAGGAAATATTTCTAAAC
A_04_P096167TATGTCTTAATTGCAGCTGTGATTGGAACGATTCAGATTGCTGTCATCTGTGTGGTGGTC
A_04_P046043AAAGACCAAACAGATCCAGGAAAAATTTCTTCTACTCGTCTCATTTCAGAAGACACAATG
A_04_P072429TGGGATGCACTGCCCATTACAGAAGTTTCAATTGAGCATGTGCAAAACTTTTATGATGGA
A_04_P088407ATCCCACTGGTCACATTTGTGTATGTCTTTGCCAATGTCGCGTATATCACTGCAATGTCC
A_04_P075700GATGCTCATATTTACCTGAACCACATTGAGCCTCTGAAAACTCAGCTTCAGCGAGAACCA
A_04_P062848TCTAACCCAGGATCTGATGGTGTTCAGGGACTACAGGCACTAACAATGACAAATTCAGCA
A_04_P069025TTATTATAAACGATGTGCTCGGTTATTAACAAGGTTGGCAGTGAGTCCACTGTGCTCACA
A_04_P066317AATCACACAGGGACACAGTTCTTTGAAATTAAGAAGAGCAGACCTCTGACAGGGCTGATG
A_04_P012981TCCATGGAACCTGCAGGTTTTTGGTGCAGGAGGACAAGCCAGCATGTGTCTGCCACTCTG
A_04_P062593GGTACTTAACAGGTATTTGGAATATGCCATCATTGTATCTCCATTTGCTTTTAATGAGAC
A_04_P075697GAAGATTTTCAGCTTGAAGGGTACAACCCACATCCAACTATTAAAATGGAGATGGCTGTT
A_04_P056382AGATACCAGGTCAACAACCTAGGACAGAGGGACCTACCGGTCAGCATCACCTTCTGGGTG
A_04_P075699CTCAGCTTCAGCGAGAACCAAGACCTTTCCCAAAGCTCAAAATTCTTCGAAAAGTTGAGA
A_04_P075047TCTAAGGAAATCATCACCTTTTGGCAGGTTATGCTCAGAAATACCACATGCCATTACTAA
A_04_P064848CTTCTCCCTGACATTCTGTGTTCAGGTGCAGAACAAGAACAAGAAAGAAAAGAAAGATAG
A_04_P080600ACTGCAATATACAAAGATGAACCTGGCTCATCGTATTTCTACACATCAGAATCTGTGGTA
A_04_P049942CTTGCCAAAGAAGCTAAAAAGGAAGATTTACTTGAAGCTAGTACCTATCATGCAGCTAAG
A_04_P013965AACAAAAATGCATTTTTGAACGACAGCGAGTGGGAACTTCTTTCTGTGTCCTCAATGTAC
A_04_P079624GGACACAGACACTGAAGAATACAAAAATGCAAAACCAAACATTAATCTTATCACTGGTCA
A_04_P042877ATGGAGAAGGCACACGGACCCTTTGTCACCAGGAAGGACCTGGAGGTAGTGGAGACAGAT
A_04_P040417TAACACCATCGTCACGATGCTCGCGTGTGTGAACCTCGTGGTGGAGTTCTGGCTGGAGAA
A_04_P062478ACAAGGACTGCTTGGTCCTTCTGAGAATATGCTTTTACGCCTTCAATCTTGTGTGCTTAT
A_04_P054449CGGGCAAATCCCTACTACTCAGAAGTTGAGCTCAATTTCATCTCTGTTTTCTGGCCACAT
A_04_P005094AAGAAGTAGTTTTGCAGAACAACCTCTGCTTTGGGAAATGTGGGTCCGTTCACTTTCCTG
A_04_P088683TTGAAAACTGCTTTGGAGAAATACCATGAAGGCATTGAAAAGGCAACAGAGGAGTGTTAT
A_04_P013087GTAGGTAGAAACTCTTCAAATCATTTCTCTTTCCTACCTCAAGTTTGTTACCTTAGAGAT
A_04_P075049GGGATCTGTTTGAATTTGTTAAAGGTGGACATTCATTTTCCAGAAGACATAAACCTTTTC
A_04_P047767GTGAAGGACATAGACATGTTTTCCATGTGTGAGCATCATCTGGTCCCATTTGTGGGAAAG
A_04_P075048TATAGAATCCATTTGGATGTCTGTCAGCTTAGACGTGTGATTGCAGCACATGGCTTTTCT
A_04_P087172TATTTATAAAATCTACTGCTACCACCACGATGAAGCGCACAGTGTCCTGGAGTCCTACGA
A_04_P069977TTTCCTCCAAGCCTGTCACATATGCCACAGTCATCTTTCCGGGAAGGGACAGGGGTGGAG
A_04_P087082GACCTGAAACAGAAACTCATCATCGGAATTTCAAATGCAGAAGGTTTTGGACTTGAGTAA
A_04_P086101CTTACGTAAAGAAATTTGATACCTTTATTCCACTTGAGCCTCTTCCACAATCTCCCAACT
A_04_P101877TGTGAATGCTGGGACGGATGGAATGGAAATGCATGTGAAATCTGGCTTGGCACAGAATAT
A_04_P098065CTTTCTTCACTGAGGGAGATAAACTTTGATGATAACCCTTTGCTGAGACCTCCAATGGAA
A_04_P020052CTTGAATGATGTCAGTTGACTGTACTGTAATGTTGTATCAACTGAATTGAATGTTTGCCT
A_04_P018421AGAGGACAAAAATCCCTTCAAGGAGCTCAAAGGAGGCTGTGTGATTTCATAAGGAAAAAA
A_04_P057677AAGTATCGCTGGTTCGCCGTCTTCTACCTGATCTTCTTCTTCTTCTTGATCCCGTTGTCG
A_04_P101879GACTGCGACAAGCATGAAGGACTCATCTGTACAGGGAATGGAATTTGTAACTGTGGAAAC
A_04_P004576ATCTTACAAGAGACAAGCCGAGGAAGCGGAGGAACAATCCAATGTCAACCTCTCCAAATT
A_04_P055525AGAGCTTCCAACCTTTGGATAAAGAAGGGTCTGAGAAGAAGCTACTGGGGGAGAATTTAG
A_04_P005121GTTTGCATGGCCTTCTTGGTTCTCAGCTTATCTAAGTCCATCCTGTTGGTCAAATTCCTC
A_04_P070787ACATACTTCCATAGAAAATCCCAAGATGACTTCTGTAGTCCTGAGCACTCAACAGAGCTA
A_04_P003182CCTCCTTTTCCTTACCATAGCATTTTGACATGCTTGAGGTATACACTGTAGCCTATTTTG
A_04_P070344TCTATATCAAGCCAATTAAGTACAGAGGTTCTATCAGAAAGGGAGACAAGCTGGGGACCC
A_04_P047768TGTGAAGGACATAGACATGTTTTCCATGTGTGAGCATCATCTGGTCCCATTTGTGGGAAA
A_04_P006369AAGTAAAGACCAGGTTCCAGAGTTAGGGGCCTTACCTAAGAGAAAAAGCACAACCTGAAA
A_04_P062481CTTACAGATTGTGAACTTTGATTCTACATACATGAATGATGATTCCATTTGGTCCTCCAA
A_04_P047771GATTGTGAAGGACATAGACATGTTTTCCATGTGTGAGCATCATCTGGTCCCATTTGTGGG
A_04_P013034GAGGATTCAATGTGGAGCTGTTGGAAGCTCTCCTCAACTACTACATTCTCAACAACCTCT
A_04_P101515AGAAGAAGCCACTTGTCAAGAGAGAAAAGCCTGAAGAATTCCAGACCCGAGTTAGAAGAG
A_04_P086097GTGTCCTTGGCCAACAGTTTATTTGCTTCTGGTGCTTTGGACTTTCCAAGACAATCCTGA
A_04_P072187AAGAACAACAAGAATATGGCCTTCAAGCTCAAGTCCAAGTCGTGCCATGACCTTTCTGTG
A_04_P101880CATTTGTTCTGCAGAAGAATGGTACATTTCGGGGGAATTCTGTGACTGTGATGACAGAGA
A_04_P012961TACATGGTGCACTGGAAGAACCAGTTCGACCATTACAGCAAGCAGGACCGCTGCTCGGAC
A_04_P062762ATCGAGAAAATCATCGGCTCCGGAGAGTCCGGGGAAGTCTGCTACGGGTGGCTACGGGTG
A_04_P004386TGATGGAAAAGTCTTCATTCATTTGTGCAACTACATCGAGCCCTGGGAGGATCTGTCCTT
A_04_P079312AGAGCTATGCAACAAGATCACAAGCAGCTTAAAAGACCACCAGAGTAAGGGACAGGCTAT
A_04_P047770ATTGTGAAGGACATAGACATGTTTTCCATGTGTGAGCATCATCTGGTCCCATTTGTGGGA
A_04_P072188CAAGAACAACAAGAATATGGCCTTCAAGCTCAAGTCCAAGTCGTGCCATGACCTTTCTGT
A_04_P034787TTCCGGAAAATGATCAAGTTCACGACGGGAAAAGAACCTTCAACCACTTACGGCTTCTAC
A_04_P084832CAAGTCTTGCTTAGAAAATCAAGAGAAGCAGAATCCATGGCAACTCACCACCTTCCATGA
A_04_P050376TCCTTTGTTACTTCAACCATAAGAGTTTCTGGAGACTGATTCTGACCCACTCTTCTGCCA
A_04_P016399CAAAACCTTTGATGACTTCCTGTTTGCCAATTCGGAACTTGAAAGGTTTGTTTCTGTCTC
A_04_P064617AATAATATCAAGCTGATTGACTTTGGTTTGAGCAACTGTGCGGGGATCCTGGGTTACTCC
A_04_P013035AGTCGGAGGATTCAATGTGGAGCTGTTGGAAGCTCTCCTCAACTACTACATTCTCAACAA
A_04_P057380ACAATATATGGCAAAAAGTGAAGAACTCTACGATTCCCTCATGAACTGTCACTGGCAGCC
A_04_P087052GAGCTGTGGCTGGGGCAGAATGAGTTTGACTTCACTGCAGACTTTCCGTCTGGTTGCTGA
A_04_P034532ATGAAGGTGGCAATGAGGAGAATATTCAGCCAGCTGCTGTGTTTCCAGAAGTTGTTTTAA
A_04_P098432CTGTTAGATCAGCTTGAAAGCAAGAAGAAAAATGCAATTTTAGCTCATGATGAACTCTAG
A_04_P079622AAACTTGTCAACATGCTTGATAAACTTTCCAGGAGAGCAGATGTGAAGGACCTGCACCAG
A_04_P086674GGATGACCTGACTAATCATGATAATTTAAAGTCTGTTGTAAATATAGGCTTTTCTGCTGG
A_04_P065378TTCTTAAACTTCTATGTTCAGACATACCAAAAAACGCCAAGGAAGAAAGATACGCAAGAG
A_04_P080267ACACTTCTCCTCACCGAAAATGAAGGTGGCAAAACTGAAGAGCAAGTCAGTTATGTATAG
A_04_P001519TTTTCTCTCATGCTGCTTGGAGTCTGTGGCTTGGCGTTTTTATCATACGCATTGTGCAAG
A_04_P001868GAAAAAATAAATGAAGGATTTGACCTGCTTCGCTCTGGGAAGAGTATTCGGACCATCCTG
A_04_P069259TTCTTTTTGACTGTCCACGACGCTATCCTCTATCTGCAGAACCAGGTGAAATCCACAAAG
A_04_P084833TTCAACCCCCTCAGCAGAACTATTCACTGGCTGAACTTGATGAGAAAATTAGTGCCCTCA
A_04_P088707AAGTGCTGGAATTTGCCATGCCTCAGAGCCACTCTGAGTTTTTCTACTCTTATTGGACAG
A_04_P084834TGGAAGGCATCTCTCCTGAATACTTTCAGTCTATAAACTTTTCTGGAAAAAGAAGAAAAG
A_04_P090269GAGGGTGATATCATCACACTCACTAATCAGATTGATGAGAACTGGTATGAAGGGATGCTT
A_04_P002343AACCTTTCAAGTTCCGAATTGGCAAACAGGAAGTCATCAAAGGTTTCGAAGAAGGTGCAG
A_04_P092610GGAAAATATCCTTTGAGGAATTCAGCACTGTGGTTAGAGGCCTGGAGTTCCACAAGAAGT
A_04_P099507GTATGATCAGAATCACATCATCCTCAACACCGTGAGCAAAGAGAAGTTAACACAGGTGTG
A_04_P047002TAAACGGTGAAGTTGAAATGGATGCTAGTATCATGGATGGAAAAGACCTGTCCACGGGAG
A_04_P081409TAAAAAGTTCTACTTCTATTCCGATGCCTACAGACCTTTGAAATTCGCGTGTGAGACTAT
A_04_P033563ATGCACAGCTCCAGAAGTTGAAAATGGAGTAAGAGTCACAGGAAATAGGAGTTTATTTTT
A_04_P031751AGGGACAAGGCGACCGACTGAGCTCAGCTGCTTATTTATTGAAAATAAACAACACAAGAG
A_04_P084752AACTACGCGACATACAGAGAAGGCTACAACGTGTATGGAACAGAGAGTGTTAAGATCTAG
A_04_P067483GAGGAGGATGTAGCATTAACTTCATATGGTACTCCCATTCAGCTGCAGACTGTTGATCCT
A_04_P065748AATCCACCTCGGAAGTAGAGAAAAAGGCAAAACAACTTGACATGGAGATGCGTCCTCTCA
A_04_P003601GGTTCTGGGAAAATCTTGACTCCTGCCAAGAAATCCTTTCTTAGACGGTTGTTTGACTAA
A_04_P061073AGATTTCTTCAAAAGAGCCCTGAACAGAGTCCTCCTGTTATTAATGCAAGCCCCGCCTAT
A_04_P076697GTTCACATTTTAAAAATTTTGTGGAAGTGGGTGGGAGAATTACAGGTATCCCTAGGCTCA

ACE: Angiotensin I converting enzyme; PRLR: Prolactin receptor; PRKCZ: Protein kinase C, zeta; LBP: Lipopolysaccharide binding protein; CYP19A1: Cytochrome P450, family 19, subfamily A, polypeptide 1; GEF: Guanine nucleotide exchange factor; UGGT2: UDP-glucose glycoprotein glucosyltransferase 2; ARHGAP11A: Activating protein 11A; LPH: Lactase phlorizin hydrolase; FKBP1B: FK506 binding protein 1B; RAG2: Recombination activating gene 2; O. cuniculus: Oryctolagus cuniculus.

Altered genes induced by chemical lesions of SA node POMC: Proopiomelanocortin, GalNAc-T6: UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6; FAM46A: Family with sequence similarity 46, member A; C. elegans: Caenorhabditis elegans; CRP: C-reactive protein; SLC17A5: Solute carrier family 17 (acidic sugar transporter), member 5; MRP-8: Macrophage migration inhibitory factor-related protein-8; KCNE2: Potassium voltage-gated channel, Isk-related family, member 2; PGR: Progesterone receptor; CA4: Carbonic anhydrase 4; STK17A: Serine/threonine kinase 17A; SOC2: Suppressor of cytokine signaling 2; PRKCZ: Protein kinase C, zeta; IFIT1B: Interferon-induced protein with tetratricopeptide repeats 1B; TE: TMEM30B: Transmembrane protein 30B; CTTNBP2: Cortactin binding protein 2; PTPRF: Protein tyrosine phosphatase, receptor type, f polypeptide; PPFIA2: Protein tyrosine phosphatase, receptor type, f polypeptide alpha 2; COL1A2: Collagen, Type I, alpha 2; BCL2L1: BCL2-like 1; SLC4A7: Solute carrier family 4, sodium bicarbonate cotransporter, member 7; GPX7: Glutathione peroxidase 7; LPXN: Leupaxin; PRLR: Prolactin receptor; O. cuniculus: Oryctolagus cuniculus; CSF: Colony stimulating factor; MMP: Matrix metallopeptidase. Differentially expressed genes ACE: Angiotensin I converting enzyme; PRLR: Prolactin receptor; PRKCZ: Protein kinase C, zeta; LBP: Lipopolysaccharide binding protein; CYP19A1: Cytochrome P450, family 19, subfamily A, polypeptide 1; GEF: Guanine nucleotide exchange factor; UGGT2: UDP-glucose glycoprotein glucosyltransferase 2; ARHGAP11A: Activating protein 11A; LPH: Lactase phlorizin hydrolase; FKBP1B: FK506 binding protein 1B; RAG2: Recombination activating gene 2; O. cuniculus: Oryctolagus cuniculus. Altered genes: A total of 11 genes were appeared in both model and SXSM originated differentially expressed genes. Click here for additional data file. Our results revealed that SXSM increased heart rate by inhibiting heart parasympathetic transmission based on the decreased CHRNA2 (encodes nicotinic acetylcholine receptor) and increased ACE-1 (encodes acetylcholinesterase) [Table 1]. They all indicate that parasympathetic synaptic transmission in heart was inhibited by SXSM. Therefore, sympathetic nerve was relatively stimulated and the heart rate increased. In addition, restored calcium handling also plays an essential role in the increased heartbeat. Both ATP2A1 (encodes calcium ATPase, SERCA2a) and FKBP1B (encodes FKBP12.6 protein, an inhibitor of calcium release channel [RyR2]) were downregulated in model group and upregulated in M+SXSM group. Therefore, restored Ca2+ stores induced by restored expression of ATP2A1and FKBP1B contribute directly to the increased heart rate through functioning similarly to sympathetic stimulation. Restored signaling also plays an important role in the effect of SXSM due to the restored MBIP, PPIC, PRKCZ, vasoactive intestinal peptide receptor (VIPR), PRLR.

Confirmation of altered gene expression by quantitative real-time reverse transcription-polymerase chain reaction

Quantitative real-time RT-PCR was performed to confirm the results from gene expression chip. Four altered genes – ATP2A1, ERP27, FKBP1B, and MBIP – were selected. The relative mRNA expression level of each selected gene was normalized to 18S rRNA. As demonstrated in Figure 2, the expression trend of mRNA expression changes as verified by real-time RT-PCR was in agreement with that detected by gene expression chip.
Figure 2

Confirmation of altered gene expression by quantitative real-time RT-PCR. (a) ATP2A1, ERP27, and FKBP1B were increased while MBIP was reduced in model vs. sham group according to real-time RT-PCR. (b) ATP2A1, ERP27, and FKBP1B were down-regulated while MBIP was upregulated in M+SXSM versus model group according to real-time RT-PCR. The relative mRNA expression level of each gene was normalized to 18S rRNA. The mRNA expression trends from real-time RT-PCR were in agreement with gene expression chip. RT-PCR: Reverse transcription-polymerase chain reaction; M+SXSM: Model plus Shenxianshengmai.

Confirmation of altered gene expression by quantitative real-time RT-PCR. (a) ATP2A1, ERP27, and FKBP1B were increased while MBIP was reduced in model vs. sham group according to real-time RT-PCR. (b) ATP2A1, ERP27, and FKBP1B were down-regulated while MBIP was upregulated in M+SXSM versus model group according to real-time RT-PCR. The relative mRNA expression level of each gene was normalized to 18S rRNA. The mRNA expression trends from real-time RT-PCR were in agreement with gene expression chip. RT-PCR: Reverse transcription-polymerase chain reaction; M+SXSM: Model plus Shenxianshengmai.

Effects of long-term Shenxianshengmai treatment on cardiac proteins

A total of 125 proteins were altered after SXSM treatment [Supplementary Table 3]. As displayed in Figure 3, the most altered proteins were those participate in oxidative phosphorylation and tricarboxylic acid (TCA) cycle. SXSM-enhanced TCA cycle due to increased aconitate hydratase, succinyl-CoA ligase (GDP-forming) subunit alpha and beta (SUCLG1/2) and succinyl-CoA ligase (ADP-forming) subunit beta (SUCLGA2), isocitrate dehydrogenase2, and dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex (DLAT, PDHB). SXSM also increased NADH dehydrogenase. The upregulated proteins include NADH dehydrogenase (complex I) core subunit (NDUFS1/3, NDUFV2), accessory subunit (NDUFS4/5), alpha (NDUFA2/7/8/9/12/13), and beta (NDUFB6) subcomplex. In addition, two subunits of mitochondrial ATP synthase (encoded by ATP5B and ATP5H) were also increased. These increased proteins may lead to enhanced mitochondrial membrane respiratory chain and increased ATP generation. All these results demonstrated that SXSM could improve the energy supplement of ventricular myocardium.
Figure 3

Altered proteins in ventricular myocardium after SXSM treatment. The most altered proteins were those participate in oxidative phosphorylation and TCA cycle. SXSM: Shenxianshengmai; TCA: Tricarboxylic acid.

Altered genes induced by SXSM treatment O. cuniculus: Oryctolagus cuniculus; CI: Confidence interval. Altered proteins in ventricular myocardium after SXSM treatment. The most altered proteins were those participate in oxidative phosphorylation and TCA cycle. SXSM: Shenxianshengmai; TCA: Tricarboxylic acid.

Confirmation of altered proteins by Western blot

Western blot was performed to confirm the results from iTRAQ. Considering the biological function, we selected two increased proteins: ATP synthase subunit beta (encoding by ATP5B) and complex I subunit (encoding by NDUFS1). β-actin was also detected as an internal control. As demonstrated in Figure 4, beta subunit of ATP synthase and subunit of complex I also increased after four weeks treatment with SXSM. This result was in agreement with that detected by iTRAQ.
Figure 4

Expression of ATP synthase subunit beta (encoding by ATP5B) and complex I subunit (encoding by NDUFS1) after SXSM treatment by Western blotting. β-actin was used as the internal protein. The results of Western blotting were from a representative of three repeated experiments. SXSM: Shenxianshengmai.

Expression of ATP synthase subunit beta (encoding by ATP5B) and complex I subunit (encoding by NDUFS1) after SXSM treatment by Western blotting. β-actin was used as the internal protein. The results of Western blotting were from a representative of three repeated experiments. SXSM: Shenxianshengmai.

Discussion

The present study shows directly or indirectly mRNA remodeling of bradycardia for the first time and demonstrates that SXSM is effective in treating bradycardia. However, it is not possible to assume that all changes in gene expression are coupled to the development of bradycardia. In fact, the present data did not exclude the possibility that the part of the gene expression modifications was associated with the SA lesion, or secondary to the development of bradycardia. Our results revealed that SXSM increased heart rate by inhibiting heart parasympathetic transmission based on the decreased CHRNA2 (encodes nicotinic acetylcholine receptor) and increased ACE-1 (encodes acetylcholinesterase). Reduced nicotinic acetylcholine receptors (encoded by CHRNA2), which form acetylcholine (ACh)-gated ion channels on the presynaptic and postsynaptic sides of the neuromuscular junction,[18] suggested the inhibition of heart parasympathetic transmission. Moreover, it is well known that acetylcholinesterase (encode by ACE-1) locates at mainly neuromuscular junctions and serves to terminate parasympathetic synaptic transmission by hydrolyzing the neurotransmitter ACh.[13] The increased expression of ACE-1 after SXSM treatment also indicates that parasympathetic synaptic transmission in heart was inhibited by SXSM. Therefore, sympathetic nerve was relatively stimulated. In addition to an increased force of heartbeat, this stimulation also causes the increase in heart rate.[14] Moreover, restored calcium handling also plays an essential role in the increased heartbeat. Bramich et al. reported that increases in force and heart rate evoked by sympathetic nerve stimulation resulted from the release of Ca2+ from intracellular Ca2+ stores-endoplasmic reticulum (ER).[14] FKBP12.6 inhibits basal RyR2 activity. PKA-dependent RyR2 phosphorylation interrupt FKBP12.6-RyR2 association and activate RyR2 in myocytes.[2223] Sarcoplasmic reticulum (SR)/ER calcium ATPases (SERCAs) are calcium pumps that couple ATP hydrolysis with calcium transport across the SR/ER membrane. As a consequence of this activity, they maintain a level of resting intra-ER free calcium that is three to four orders of magnitude higher than the cytosolic Ca2+ concentration.[19] Reduced SR Ca2+ release is due to diminished SR Ca2+ content directly related to a depressed expression of SERCA2a protein. Enhancing SERCA2a expression may improve SR Ca2+ handling in failing human myocardium.[20] From our results, both ATP2A1 and FKBP1B were downregulated in model group and upregulated in M+SXSM group. Therefore, restored Ca2+ stores induced by restored expression of SERCA2a and FKBP12.6 contributed directly to increased heart rate. Previous studied suggested that reduced ACE (encodes angiotensin I converting enzyme) may contribute to the improvement of heart function.[35] Hence, reduced ACE after SXSM treatment may also play a positive role in heart. In addition, restored signaling also play an important role in the effect of SXSM due to the restored MBIPth, PPIC, PRKCZ, VIPR, and PRLR. MBIP interacts with MUK/DLK/ZPK (a MAPKKK class protein kinase) and inhibits the activity of it to induce JNK/SAPK activation.[25] The protein encoded by PPIC is a member of the PPIase family. PPIases catalyze the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerate the folding of proteins.[26] Along with PPIB, PPIC localizes to the ER, where it maintains redox homeostasis.[27] Increasing evidence from studies using in vitro and in vivo systems points to PKC zeta (PRKCZ) as a key regulator of critical intracellular signaling pathways such as mitogen-activated protein kinase cascade, transcriptional factor nuclear factor-kappa B activation, ribosomal S6-protein kinase signaling, and cell polarity.[28] VIPR is a receptor for vasoactive intestinal peptide. The activity of it is mediated by G proteins which activate adenylyl cyclase.[29] The PRLR is a cytokine receptor, and second messenger cascades include the JAK-STAT pathway, JAK-RUSH pathway, Ras-Raf-MAPK, and PI3K/AKT/mTOR pathway.[30] In ventricular myocardium, SXSM increased the supply of ATP by enhancing TCA cycle and oxidation-respiratory chain. Upregulated proteins ranged from enzymes of TCA cycle to subunits of complex I and ATP synthase. It was well known that mitochondrial ATP synthase catalyzes ATP synthesis.[36] It included two complexes: the soluble catalytic core, F1, and the membrane-spanning component, F0, which comprises the proton channel. The F1 complex consists of 5 different subunits (alpha, beta, gamma, delta, and epsilon). The F0 seems to have nine subunits (a, b, c, d, e, f, g, and F6 and 8).[37] According to our results, the increased ATP5B and ATP5H encode the beta subunit of F1 and d subunit of the F0 complex, respectively. Thus, ATP generation was effectively enhanced in ventricular myocardium. In conclusion, our bradycardia model showed that long-term SXSM stimulate sympathetic transmission by increasing the expression of acetylcholinesterase and reduce the expression of nicotinic receptor to increase heart rate. SXSM also restored the calcium handling genes and altered genes involved in signaling. In addition, SXSM improves the ATP supply of ventricular myocardium by increasing proteins involved in TCA cycle and oxidation-respiratory chain. These data provide insights for the future study of SXSM. Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Financial support and sponsorship

This work was supported by the grant from the International S&T Cooperation Program of China (No. 2013DFA31620).

Conflicts of interest

There are no conflicts of interest.
Supplementary Table 3

Altered genes induced by SXSM treatment

Differential protein summary

Protein numberRepresentative accessionGeneSpeciesNameLog 115:114
55gi|291394365ACAA2O. cuniculusPredicted: 3-ketoacyl-CoA thiolase, mitochondrial (O. cuniculus)0.328
17gi|655884414ACO2O. cuniculusPredicted: Aconitate hydratase, mitochondrial (O. cuniculus)0.624
87gi|291405797ACSF2O. cuniculusPredicted: Acyl-CoA synthetase family member 2, mitochondrial (O. cuniculus)0.308
33gi|655885133ACSS1O. cuniculusPredicted: acetyl-coenzyme A synthetase 2-like, mitochondrial (O. cuniculus)0.484
29gi|291402113ACTN2O. cuniculusPredicted: Alpha-actinin-2 (O. cuniculus)−0.404
1020gi|655866030ADKO. cuniculusPredicted: Adenosine kinase isoform X1 (O. cuniculus)0.308
531gi|655896110ADPRHL1Protein ADP-ribosylargininePredicted: (Protein ADP-ribosylarginine) hydrolase-like protein 1 (O. cuniculus)−0.664
447gi|655859663AGTO. cuniculusPredicted: Angiotensinogen (O. cuniculus)−0.440
4gi|655882084AHNAKO. cuniculusPredicted: Neuroblast differentiation-associated protein AHNAK isoform X8 (O. cuniculus)−0.472
1372gi|389886569AKR1B10O. cuniculusAldo-keto reductase family 1 member B10 (O. cuniculus)−0.468
92gi|42558920ALDH1A1RABITRecName: full=Retinal dehydrogenase 1; Short=RALDH 1; Short=RalDH1; AltName: Full=ALDH-E1; AltName: Full=ALHDII; AltName: Full=Aldehyde dehydrogenase family 1 member A1; AltName: Full=Aldehyde dehydrogenase, cytosolic−0.416
109gi|655851269ALDH4A1O. cuniculusPredicted: Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (O. cuniculus)0.328
199gi|655862574ANXA2O. cuniculusPredicted: Annexin A2 (O. cuniculus)−0.300
132gi|655601008APOA1O. cuniculusPredicted: Apolipoprotein A-I isoform X1 (O. cuniculus)−1.848
144gi|284005104APOA4O. cuniculusApolipoprotein A-IV precursor (O. cuniculus)−0.436
14gi|655739959ATP5BO. cuniculusPredicted: ATP synthase subunit beta, mitochondrial (O. cuniculus)0.344
207gi|291413480ATP5HO. cuniculusPredicted: ATP synthase subunit d, mitochondrial (O. cuniculus)0.384
466gi|291411267AZGP1O. cuniculusPredicted: Zinc-alpha-2-glycoprotein (O. cuniculus)−0.480
923gi|655838631BASP1O. cuniculusPredicted: Brain acid soluble protein 1 (O. cuniculus)−0.740
1203gi|291411015BCKDK2721777.1Predicted: [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial (O. cuniculus)0.340
243gi|291400445BDH1O. cuniculusPredicted: D-beta-hydroxybutyrate dehydrogenase, mitochondrial (O. cuniculus)0.336
582gi|655815890CALD1O. cuniculusPredicted: Caldesmon isoform X1 (O. cuniculus)−0.492
154gi|291384816CATO. cuniculusPredicted: Catalase (O. cuniculus)−0.328
283gi|655832713CLYBLO. cuniculusPredicted: Citrate lyase subunit beta-like protein, mitochondrial (O. cuniculus)−0.352
461gi|655897425COX4I1O. cuniculusPredicted: Cytochrome c oxidase subunit 4 isoform 1, mitochondrial (O. cuniculus)0.328
167gi|655852771CPO. cuniculusPredicted: Ceruloplasmin isoform X2 (O. cuniculus)−0.668
208gi|729207CRYABRABITRecName: Full=Alpha-crystallin B chain; AltName: Full=Alpha(B)-crystallin−1.024
505gi|655833140CTNNB1O. cuniculusPredicted: Catenin beta-1 (O. cuniculus)−0.552
504gi|655901408CTSDO. cuniculusPredicted: Cathepsin D (O. cuniculus)−0.368
178gi|291398429DBTO. cuniculusPredicted: Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial (O. cuniculus)0.368
535gi|655761595DDX17O. cuniculusPredicted: Probable ATP-dependent RNA helicase DDX17 (O. cuniculus)−0.356
424gi|655840060DDX39BO. cuniculusPredicted: Low quality protein: Spliceosome RNA helicase DDX39B (O. cuniculus)−0.380
576gi|913375decorinO. cuniculusDecorin (O. cuniculus)−0.412
210gi|291383892DLATO. cuniculusPredicted: Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial (O. cuniculus)0.328
696gi|655858948ECHDC3O. cuniculusPredicted: Enoyl-CoA hydratase domain-containing protein 3, mitochondrial isoform X2 (O. cuniculus)0.452
124gi|291399590ENO1O. cuniculusPredicted: Alpha-enolase (O. cuniculus)−0.444
2070gi|291394172ENOSF1O. cuniculusPredicted: Mitochondrial enolase superfamily member 1 (O. cuniculus)−0.516
322gi|32363162EZRRABITRecName: full=Ezrin; AltName: Full=Cytovillin; AltName: Full=Villin-2; AltName: Full=p81−0.412
103gi|291401111FGAO. cuniculusPredicted: Fibrinogen alpha chain (O. cuniculus)0.584
204gi|291401109FGBO. cuniculusPredicted: Fibrinogen beta chain (O. cuniculus)0.516
289gi|655856160FGGO. cuniculusPredicted: Fibrinogen gamma chain isoform X2 (O. cuniculus)0.592
45gi|284004982FLNAO. cuniculusFilamin-A (O. cuniculus)−0.408
490gi|655835149FLNBO. cuniculusPredicted: Filamin-B isoform X7 (O. cuniculus)−0.300
1284gi|655882129FTH1O. cuniculusPredicted: Ferritin heavy chain (O. cuniculus)−0.528
791gi|655848679FUBP1O. cuniculusPredicted: Far upstream element-binding protein 1 isoform X15 (O. cuniculus)−0.344
276gi|291416166GSTP1O. cuniculusPredicted: Glutathione S-transferase P (O. cuniculus)−0.324
476gi|655733800HNRNPA1O. cuniculusPredicted: Heterogeneous nuclear ribonucleoprotein A1 isoform X3 (O. cuniculus)−0.384
864gi|655887639HNRNPMO. cuniculusPredicted: Low quality protein: Heterogeneous nuclear ribonucleoprotein M (O. cuniculus)−0.516
986gi|291406576HSPA2O. cuniculusPredicted: Heat shock-related 70 kDa protein 2 (O. cuniculus)−0.436
116gi|291390901HSPB1O. cuniculusPredicted: Heat shock protein beta-1 (O. cuniculus)−0.428
18gi|291391974HSPD1O. cuniculusPredicted: 60 kDa heat shock protein, mitochondrial (O. cuniculus)0.596
38gi|291410533IDH2NADPPredicted: Isocitrate dehydrogenase [NADP], mitochondrial (O. cuniculus)0.632
1004gi|291406081KRT19O. cuniculusPredicted: Keratin, Type I cytoskeletal 19 (O. cuniculus)−0.800
536gi|655730920KRT8O. cuniculusPredicted: Keratin, Type II cytoskeletal 8 (O. cuniculus)−1.096
361gi|291392980LCP1O. cuniculusPredicted: Plastin-2 (O. cuniculus)−0.532
158gi|291404101LDB3O. cuniculusPredicted: LIM domain-binding protein 3 isoform X4 (O. cuniculus)−0.472
345gi|655846237LMNAO. cuniculusPredicted: Lamin isoform X1 (O. cuniculus)−0.428
400gi|655855761LOC100339009O. cuniculusPredicted: ATP synthase-coupling factor 6, mitochondrial-like (O. cuniculus)0.420
196gi|291386253LOC100343793O. cuniculusPredicted: Cytochrome c oxidase subunit 5B, mitochondrial (O. cuniculus)0.428
1135gi|655885637LOC100344952O. cuniculusPredicted: Histone H2B type 1 (O. cuniculus)−0.488
1947gi|655852407LOC100345698O. cuniculusPredicted: Inhibitor of carbonic anhydrase-like isoform X1 (O. cuniculus)−0.592
127gi|655887883LOC100346411O. cuniculusPredicted: Cytochrome c oxidase subunit 5A, mitochondrial (O. cuniculus)0.432
549gi|655839888LOC100349084O. cuniculusPredicted: Histone H1.2 (O. cuniculus)−0.504
1633gi|655878767LOC100349190O. cuniculusPredicted: Low quality protein: growth Arrest and DNA damage-inducible proteins-interacting protein 1-like (O. cuniculus)0.344
108gi|655831556LOC100352842O. cuniculusPredicted: Alpha-2-macroglobulin (O. cuniculus)0.312
940gi|655831559LOC100353846O. cuniculusPredicted: Alpha-2-macroglobulin-like isoform X1 (O. cuniculus)−0.340
288gi|291395803LOC100354435O. cuniculusPredicted: Heat shock 70 kDa protein 1B-like (O. cuniculus)−0.360
464gi|655843262LOC100357329O. cuniculusPredicted: Cytochrome c (O. cuniculus)0.464
1105gi|655602638LOC100357801O. cuniculusPredicted: Interferon-induced very large GTPase 1-like isoform X2 (O. cuniculus)0.356
297gi|655901721LOC100357978O. cuniculusPredicted: Low quality protein: EH domain-containing protein 1-like (O. cuniculus)−0.300
129gi|655837463LOC100358789O. cuniculusPredicted: Low quality protein: dihydrolipoyl dehydrogenase, mitochondrial-like (O. cuniculus)0.368
274gi|307574681LUMO. cuniculusLumican precursor (O. cuniculus)−0.652
6gi|655603999MYBPC3O. cuniculusPredicted: Myosin-binding protein C, cardiac-type (O. cuniculus)−0.444
107gi|655864030MYH6O. cuniculusPredicted: Low quality protein: Myosin-6 (O. cuniculus)1.052
1gi|291403583MYH7O. cuniculusPredicted: Low quality protein: myosin-7 (O. cuniculus)−1.340
156gi|291406966MYL2O. cuniculusPredicted: Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (O. cuniculus)−1.008
149gi|291393583MYL3O. cuniculusPredicted: Myosin light chain 3 (O. cuniculus)−0.560
478gi|291401801MYOZ2O. cuniculusPredicted: Myozenin-2 (O. cuniculus)−0.392
539gi|655601573NCAM1O. cuniculusPredicted: Neural cell adhesion molecule 1 isoform X6 (O. cuniculus)−0.472
720gi|291389739NDUFA122711251.1Predicted: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 (O. cuniculus)0.428
474gi|655898789NDUFA138250959.1Predicted: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (O. cuniculus)0.488
814gi|655645211NDUFA22710300.2Predicted: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 (O. cuniculus)0.396
722gi|291411555NDUFA72722046.1Predicted: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 (O. cuniculus)0.716
931gi|655878802NDUFA88271654.1Predicted: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 (O. cuniculus)0.424
193gi|291392701NDUFA92712902.1Predicted: NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (O. cuniculus)0.436
956gi|291383105NDUFB62708084.1Predicted: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (O. cuniculus)0.344
63gi|291392087NDUFS1O. cuniculusPredicted: NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (O. cuniculus)0.340
258gi|291384976NDUFS32709147.1Predicted: NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (O. cuniculus)0.452
578gi|655839067NDUFS48260420.1Predicted: NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial (O. cuniculus)0.456
794gi|291399216NDUFS52715247.1Predicted: NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 (O. cuniculus)0.500
318gi|291394118NDUFV22713628.1Predicted: NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (O. cuniculus)0.524
527gi|655848695NEXNO. cuniculusPredicted: Nexilin isoform X3 (O. cuniculus)−0.508
712gi|75073382OGNRABITRecName: Full=Mimecan; AltName: Full=Osteoglycin; Flags: Precursor−0.476
114gi|291395294OXCT1O. cuniculusPredicted: Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (O. cuniculus)0.400
155gi|283549170P4HBO. cuniculusProtein disulfide-isomerase precursor (O. cuniculus)−0.384
213gi|291393915PDHBO. cuniculusPredicted: Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (O. cuniculus)0.324
232gi|655603453PDHXO. cuniculusPredicted: Pyruvate dehydrogenase protein X component, mitochondrial (O. cuniculus)0.368
544gi|655857157PDLIM5O. cuniculusPredicted: PDZ and LIM domain protein 5 isoform X5 (O. cuniculus)−0.396
965gi|655600179PLIN2O. cuniculusPredicted: Perilipin-2 isoform X2 (O. cuniculus)−0.612
1041gi|291409678POSTNO. cuniculusPredicted: Periostin isoform X3 (O. cuniculus)−0.472
228gi|291404901PRDX3O. cuniculusPredicted: Thioredoxin-dependent peroxide reductase, mitochondrial (O. cuniculus)0.332
135gi|291397244PRDX6O. cuniculusPredicted: Peroxiredoxin-6 (O. cuniculus)−0.372
493gi|655899020RCN3O. cuniculusPredicted: Reticulocalbin-3 (O. cuniculus)−0.416
368gi|291414084SERPINA3O. cuniculusPredicted: Alpha-1-antichymotrypsin (O. cuniculus)−0.400
278gi|655868465SERPINF2O. cuniculusPredicted: Alpha-2-antiplasmin isoform X2 (O. cuniculus)−0.692
1859gi|655604153SF3B2O. cuniculusPREDICTED: splicing factor 3B subunit 2 (O. cuniculus)−0.576
659gi|655865891SNCGO. cuniculusPREDICTED: gamma-synuclein (O. cuniculus)−0.388
458gi|655844284SOD2MnPredicted: Superoxide dismutase [Mn], mitochondrial (O. cuniculus)0.392
1207gi|655851673STMN1O. cuniculusPredicted: Stathmin isoform X4 (O. cuniculus)−0.520
146gi|655880099SUCLA2ADP-formingPredicted: Succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial isoform X1 (O. cuniculus)0.324
363gi|291386439SUCLG1ADP/GDP-formingPredicted: Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial (O. cuniculus)0.908
46gi|291393975SUCLG2GDP-formingPredicted: Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial (O. cuniculus)0.568
338gi|291383827TAGLNO. cuniculusPredicted: Transgelin (O. cuniculus)−0.544
84gi|655704650TGM2O. cuniculusPredicted: Protein-glutamine gamma-glutamyltransferase 2 (O. cuniculus)0.580
1656gi|291403258THBS1O. cuniculusPredicted: Thrombospondin-1 (O. cuniculus)0.336
236gi|291393813TNNC1O. cuniculusPredicted: Troponin C, slow skeletal and cardiac muscles (O. cuniculus)−0.648
157gi|291392777TPI1O. cuniculusPredicted: Triosephosphate isomerase (O. cuniculus)0.360
200gi|655892501TRAP1O. cuniculusPredicted: Heat shock protein 75 kDa, mitochondrial (O. cuniculus)0.404
3gi|655828141TTNO. cuniculusPredicted: Low quality protein: Titin (O. cuniculus)−0.404
249gi|655894873WARSO. cuniculusPredicted: Tryptophan-tRNA ligase, cytoplasmic isoform X1 (O. cuniculus)−0.312
8gi|6459859590Chain A, crystal structure of leporine serum albumin in complex with naproxen−0.396
902gi|15420611O. cuniculusPKA catalytic subunit alpha (O. cuniculus)−0.364
928gi|349538O. cuniculusGlutathione S-transferase (O. cuniculus)−0.356
609gi|559973O. cuniculusAldose reductase (O. cuniculus)−0.332
24gi|298544459O. cuniculusUnnamed protein product (O. cuniculus)0.372

Differential protein summary

Protein numberLog 116:114Log P value 115:114Log P value 116:114

550.328−5.299−6.378
170.188−9.196−1.975
87−0.256−3.019−0.149
330.204−6.738−4.083
29−0.212−6.730−2.697
1020−0.196−1.493−0.178
5310.084−2.558−0.367
4470.396−1.569−2.721
40.020−15.654−1.477
1372−0.276−1.375−0.914
92−0.224−2.658−0.716
1090.336−3.895−2.504
199−0.016−3.142−0.059
1320.028−3.097−0.145
144−0.204−6.978−3.467
14−0.428−2.757−0.688
207−0.032−1.578−0.295
4660.216−2.508−1.466
923−0.484−3.666−2.878
12030.180−1.410−0.650
243−0.068−2.253−0.688
5820.036−3.998−0.385
154−0.056−5.039−0.136
2830.044−3.217−0.515
461−0.144−1.641−0.607
1670.864−1.682−12.422
2080.076−1.878−1.434
505−0.268−2.764−1.444
504−0.272−2.422−1.042
1780.020−3.010−0.030
535−0.100−2.291−0.471
424−0.028−1.475−0.026
576−0.176−2.354−0.429
210−0.060−3.624−0.066
6960.424−1.965−1.903
1240.056−3.234−1.963
2070−0.208−1.398−0.659
3220.308−2.380−2.404
1030.872−4.441−7.153
2040.788−3.570−6.348
2890.904−5.325−8.654
450.108−7.676−1.941
4900.020−1.833−0.095
1284−0.176−1.597−0.433
7910.016−1.584−0.177
276−0.164−1.542−0.831
476−0.012−1.307−0.285
864−0.184−2.309−0.725
986−0.052−2.180−0.025
1160.060−2.987−0.133
180.384−9.784−5.614
380.056−4.168−4.594
10040.064−2.884−0.200
536−0.104−5.187−0.580
3610.088−4.075−0.488
158−0.296−4.023−3.094
840.024−8.826−0.084
16560.460−1.358−1.907
236−0.496−4.662−0.561
1570.468−2.575−6.461
2000.160−1.696−0.138
3−0.092−16.000−0.727
2490.064−2.159−0.597
80.192−3.434−5.032
902−0.256−2.069−0.618
928−0.036−1.891−0.077
609−0.056−1.450−0.080
240.256−1.471−4.083

O. cuniculus: Oryctolagus cuniculus; CI: Confidence interval.

  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Mechanism of the F(1)F(0)-type ATP synthase, a biological rotary motor.

Authors:  Roderick A Capaldi; Robert Aggeler
Journal:  Trends Biochem Sci       Date:  2002-03       Impact factor: 13.807

3.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

Review 4.  Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

Authors:  Robert W Neumar; Charles W Otto; Mark S Link; Steven L Kronick; Michael Shuster; Clifton W Callaway; Peter J Kudenchuk; Joseph P Ornato; Bryan McNally; Scott M Silvers; Rod S Passman; Roger D White; Erik P Hess; Wanchun Tang; Daniel Davis; Elizabeth Sinz; Laurie J Morrison
Journal:  Circulation       Date:  2010-11-02       Impact factor: 29.690

5.  Modulation by intracellular Ca2+ of the hyperpolarization-activated inward current in rabbit single sino-atrial node cells.

Authors:  N Hagiwara; H Irisawa
Journal:  J Physiol       Date:  1989-02       Impact factor: 5.182

6.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

7.  How does adrenaline accelerate the heart?

Authors:  H F Brown; D DiFrancesco; S J Noble
Journal:  Nature       Date:  1979-07-19       Impact factor: 49.962

8.  Transgenic analysis of the role of FKBP12.6 in cardiac function and intracellular calcium release.

Authors:  Ying Liu; Hanying Chen; Guangju Ji; Baiyan Li; Peter J Mohler; Zhiming Zhu; Weidong Yong; Zhuang Chen; Xuehong Xu; Hongbo Xin; Weinian Shou
Journal:  Assay Drug Dev Technol       Date:  2011-11-16       Impact factor: 1.738

Review 9.  Protein kinase Czeta (PKCzeta): activation mechanisms and cellular functions.

Authors:  Takaaki Hirai; Kazuhiro Chida
Journal:  J Biochem       Date:  2003-01       Impact factor: 3.387

10.  ACE2 gene expression is up-regulated in the human failing heart.

Authors:  Andrew B Goulter; Martin J Goddard; Jennifer C Allen; Kenneth L Clark
Journal:  BMC Med       Date:  2004-05-19       Impact factor: 8.775

View more
  3 in total

1.  CLIN_SKAT: an R package to conduct association analysis using functionally relevant variants.

Authors:  Amrita Chattopadhyay; Ching-Yu Shih; Yu-Chen Hsu; Jyh-Ming Jimmy Juang; Eric Y Chuang; Tzu-Pin Lu
Journal:  BMC Bioinformatics       Date:  2022-10-23       Impact factor: 3.307

2.  Traditional Chinese Medicine for Bradyarrhythmia: Evidence and Potential Mechanisms.

Authors:  Shuo Liu; Guihua Tian; Jing Chen; Xiaoyu Zhang; Aiming Wu; Min Li; Yang Sun; Baoshan Liu; Yanwei Xing; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-04-09       Impact factor: 5.810

Review 3.  Therapeutic Effects of Traditional Chinese Medicine on Cardiovascular Diseases: the Central Role of Calcium Signaling.

Authors:  Yuxin Li; Zhang Zhang; Sen Li; Tingting Yu; Zhaoqi Jia
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.